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1.1 Identification and characterization of Cripto antagonists 
to improve the use of stem cell-based therapy in 
neurodegenerative disorders 
 
  Recent breakthroughs in stem cell research underscore the importance of 
controlling stem cell differentiation for the success of cell-based transplantation 
therapies in neurodegenerative diseases, such as Parkinson Disease (PD). In this 
regard, Embryonic Stem (ES) cells have been shown to serve as a source for 
deriving the optimal dopaminergic (DA) cells to restore the nigrostriatal system. 
However, our knowledge about the molecular mechanisms implicated in the 
determination of the neural fate in ES cells is still incomplete and thus their 
differentiation is poorly controlled. Recent findings from our laboratory indicate that 
the EGF-CFC protein Cripto is a key player in the signaling pathways that control 
neural differentiation of ES cells. Cripto is a GPI-anchored protein and a co-receptor 
for Nodal, a TGF-! family ligand. Cripto-dependent Nodal signaling is required for 
early embryogenesis; this signaling depends on the Activin type II serine/threonine 
kinase receptor (ActRII) and the Activin type I serine/threonine kinase receptor 
(Alk4), which, once activated, phosphorylate the downstream transcriptional 
coactivator Smad2. Cripto is strictly required for ES cell differentiation to 
cardiomyocytes and it negatively regulates neuronal differentiation of ES cells; 
indeed, disruption of Cripto in ES cells results in increased dopaminergic 
differentiation and reducted tumor formation, upon transplantation in rat models of 
PD. As an extracellular molecule, Cripto is a promising target for therapy. The 
specific aims of my projecy are: a) to identify molecules able to inhibit Cripto/receptor 
interaction by exploiting a powerful experimental approach based on the use of 
combinatorial chemistry; b) to improve the therapeutic potential of ES cells for cell 
replacement therapy in PD. We have thus exploited a novel experimental approach 
based on the use of combinatorial chemistry combined to ES cell differentiation. By 
using an ELISA-based assay, we previously identified a tetrameric tripeptide able to 
block efficiently the Cripto/ Alk4receptor interaction. 
Our results show that this blocking peptides, by inhibiting the endogenous Cripto 
signaling, impairs cardiac differentiation and redirects the differentiation of ES cells to 
a neural fate. In addition, the Cripto/Alk4 Blocking peptide promotes ES cell 
differentiation to dopaminegic neurons.  
All together our data provide evidence that, through the addition of small, non-toxic 
activators/inhibitors of signaling pathways, the differentiation of pluripotent ES cells 
might be controlled for the production of specific cell types, suitable for the use in 
animal model of human disease. Worth noting, the ability to direct ES cell fate solely 
through the use of extracellular factors, without the need to manipulate ES cells 
genetically, may permit a direct extension of this strategy to human cells. 
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 1.2 Identificazione e caratterizzazione di antagonisti di 
Cripto per migliorare l’uso delle cellule staminali in malattie 
neurodegenerative 
 
  La riparazione di tessuti ed organi danneggiati è una necessità per la 
sopravvivenza di tutti gli individui. In questa prospettiva, il trapianto cellulare 
rappresenta una grande opportunità per sopperire all’incapacità di diversi tessuti 
dell’organismo adulto di sostituire le parti lese. Il successo di tale strategia è limitato 
dall’accesso alla preparazione ed alla disponibilità di cellule altamente specializzate 
nonchè alla non omogeneità dei tipi cellulari prodotti. In questo scenario, le cellule 
staminali embrionali (ES) rappresentano una sorgente ottimale per ottenere diversi 
tipi di cellule differenziate, grazie alla loro capacità di replicarsi un numero illimitato 
di volte e di dare origine a qualsiasi tipo cellulare specializzato dell’organismo 
adulto. Inoltre, tali cellule rappresentano un ottimo sistema modello per studiare i 
meccanismi molecolari che controllano le prime fasi dello sviluppo dei mammiferi e 
quindi i processi di specificazione e differenziamento dei diversi lineages cellulari. 
Tali meccanismi sono al momento ancora largamente sconosciuti e suscitano 
notevole interesse. Infatti, studi emergenti da differenti campi di ricerca fanno 
ipotizzare  che le stesse molecole e meccanismi che operano durante lo sviluppo 
embrionale sono anche coinvolti in processi, sia fisiologici che patologici, attivi 
nell'adulto. Ad esempio, l'associazione tra embriogenesi e tumorigenesi è molto 
forte e sta aprendo nuove strade nella ricerca oncologica. 
Studi recenti condotti sulle cellule staminali sottolineano l’importanza di controllare il 
differenziamento delle stesse per il successo della terapia cellulare in malattie 
neurodegenerative come il Parkinson [1]. È stato dimostrato, infatti, che le cellule 
ES, possono essere un’ottima risorsa per ottenere neuroni dopaminergici da 
utilizzare per il trapianto [2]. Tuttavia, l’impiego delle ES in approcci di medicina 
rigenerativa ha un grosso limite legato alla presenza di cellule indifferenziate che 
possono dar origine alla formazione e allo sviluppo di teratomi. Ne consegue, quindi, 
che la comprensione dei meccanismi molecolari alla base dei processi di 
specificazione e differenziamento dei diversi lineages cellulari nei mammiferi è 
fondamentale al fine di i) controllare il differenziamento delle cellule staminali a 
scopi terapeutici in approcci di medicina rigenerativa e ii) di identificare pathways di 
trasduzione del segnale attivi in processi biologici strettamente correlati come 
l’embriogenesi e la tumorigenesi.  
In questo scenario, il gene cripto svolge un ruolo chiave. Cripto/TDGF-1 
(teratocarcinoma-derived growth factor-1) è il capostipite della famiglia delle 
proteine extracellulari EGF-CFC, caratteristiche dei vertebrati, a cui appartengono 
FRL-1 in Xenopus, oep (one-eyed-pinhead) in Zebrafish, Cripto e cryptic nel topo e 
nell’uomo [3]. Tutte le proteine della famiglia EGF-CFC mostrano caratteristiche 
strutturali comuni: una regione idrofobica all'estremità N-terminale che ne media la 
secrezione, una regione EGF-simile, una regione CFC (da cripto, FRL-1, cryptic ) 
caratterizzata da sei cisteine la cui spaziatura è conservata ed infine una piccola 
regione idrofobica all'estremità C-terminale. 
Cripto è espresso sia nelle cellule ES che durante le fasi precoci dello sviluppo 
embrionale, mentre nell’adulto la sua espressione è riattivata in diversi tumori quali il 
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carcinoma del colon, del pancreas, ovarico e della mammella, in contrasto con i 
corrispondenti tessuti normali in cui l’espressione è sempre assente [3], [4]. 
Funzioni diverse del gene cripto in processi biologici fondamentali hanno suscitato 
notevole interesse: il suo ruolo chiave nello sviluppo embrionale precoce [5], nel 
differenziamento delle cellule ES [6], [7] e, non ultimo, nella progressione tumorale 
[8]. 
Durante il differenziamento delle cellule ES cripto svolge un ruolo chiave nel 
differenziamento cardiaco. In appropriate condizioni colturali le cellule ES possono 
essere indotte a formare strutture tridimensionali, chiamate corpi embrioidi (EBs) in 
grado di dare origine ai tre foglietti embrionali (endoderma, mesoderma ed 
ectoderma) ed a tutte le cellule caratteristiche dei tre foglietti. Cripto svolge un ruolo 
fondamentale nella specificazione di uno di questi tre foglietti, il mesoderma, ed in 
particolare è strettamente necessario per la formazione delle cellule cardiache. È 
stato, infatti, dimostrato che cellule ES cripto-/- perdono selettivamente la capacità di 
formare cardiomiociti contrattili mentre acquisiscono spontaneamente, senza 
l’aggiunta di induttori specifici, la capacità di differenziare in neuroni. Inoltre, le cellule 
ES cripto-/- differenziano efficientemente in neuroni dopaminergici e sono in grado, 
impiantate nel cervello di ratti parkinsoniani, di recuperare il fenotipo senza dare 
origine alla formazione di teratomi [9]. 
Cripto, quindi, agisce come interruttore molecolare: la sua presenza rende possibile il 
differenziamento delle cellule ES in cardiomiociti, mentre la sua assenza rende 
queste cellule capaci di differenziare in neuroni. 
Approcci genetici e biochimici, hanno dimostrato che Cripto funziona come co-
recettore di Nodal, un ligando della famiglia del TGF-! [10], [6]. Il signaling di Nodal 
dipendente da Cripto è richiesto nello sviluppo embrionale precoce, esso agisce 
attraverso il complesso recettoriale formato dal recettore dell’Activina di tipo I 
(ALK4) e dal recettore tipo II (ActRII); tale complesso, una volta attivato, induce la 
fosforilazione dell’effettore intracellulare Smad2.  
Il progetto di ricerca  è stato volto, quindi, all’identificazione e caratterizzazione di 
molecole che agissero da antagonisti dell’interazione Cripto/recettore Alk4, da 
utilizzare come inibitori del signaling endogeno di Cripto, allo scopo di indurre il 
differenziamento neurale delle ES e allo stesso tempo di inibire la formazione di 
tessuti di derivazione mesodermica. 
La strategia sperimentale eseguita è stata quella di accoppiare la chimica 
combinatoriale con il differenziamento delle cellule ES. 
Le librerie peptidiche fin dal 1990 sono state ampiamente utilizzate per selezionare 
nuove molecole attive, determinando un’innovazione nella ricerca molecolare e nella 
scoperta di nuovi farmaci. Il punto di forza nell’uso della chimica combinatoriale è la 
sintesi di ligandi ad alta affinità per l’analisi e la manipolazione di interazioni 
biochimiche. Le librerie peptidiche mostrano numerosi vantaggi, tra i quali:  la 
completa automazione della sintesi, la sintesi di un alto numero di molecole in tempi 
ridotti e l’ottenimento di popolazioni omogenee di peptidi che ne facilitano la 
caratterizzazione.  
Partendo da una libreria peptidica composta da 27.000 molecole differenti, mediante 
un saggio di tipo ELISA, è stato identificato un peptide capace di inibire 
efficacemente il legame di Cripto al recettore Alk4, rispetto ai peptidi di controllo che 
non interferivano il legame Cripto/Alk4. 
È stato dimostrato che il Peptide bloccante è in grado di legare specificamente Cripto 
e non il recettore Alk4. Inoltre, per determinare il contributo della struttura tetramerica 
all’attività del peptide bloccante, è stata sintetizzata la forma analoga dimerica e la 
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trimerica ed è stato dimostrato che tali forme non inibiscono (la forma dimerica) o 
inibiscono con una bassa efficienza (la forma trimerica) l’interazione di Cripto al 
recettore, dimostrando, quindi, l’importanza della struttura tetramerica per l’attività del 
peptide. Come discusso precedentemente, le cellule ES cripto-/- differenziano 
spontaneamente in neuroni; questo fenotipo può essere completamente recuperato 
dall’aggiunta esogena della proteina Cripto ricombinante in una precisa finestra 
temporale (0-2 giorni del differenziamento). L’aggiunta di Cripto alle cellule ES cripto-
/- induce la fosforilazione dell’effettore intracellulare Smad2.  
Per prima cosa ci siamo chiesti se il Peptide bloccante fosse in grado di bloccare il 
signaling di Cripto e di mimare gli effetti dell’assenza del gene. Abbiamo, quindi, 
valutato se il Peptide bloccante fosse in grado di inibire la fosforilazione di Smad2 
indotta dall'aggiunta della proteina Cripto. Mediante analisi di Western blot, effettuata 
su estratti proteici da corpi embrioidi (EBs), derivati dalle cellule cripto-/- e trattati con 
la proteina Cripto in presenza di quantità crescenti del peptide bloccante o del 
peptide di controllo, abbiamo dimostrato che soltanto il Peptide bloccante era in 
grado di inibire completamente la fosforilazione di Smad2, mostrando livelli 
paragonabili a quelli delle cellule ES cripto-/- di controllo. 
La disponibilità di una molecola in grado di antagonizzare l’attività di Cripto potrebbe 
rappresentare un potente strumento per analizzare il ruolo funzionale di tale gene nel 
differenziamento delle cellule ES.  
Sulla base di queste considerazioni e dai precedenti risultati, il Peptide bloccante è 
stato usato sulle cellule ES wild type per determinare la sua capacità di inibire il 
signaling endogeno di Cripto e quindi di bloccare il differenziamento cardiaco e 
reindirizzarlo verso quello neurale, così come si osserva in assenza del gene.  Per 
valutare la specificità del Peptide bloccante, è stato analizzato il suo effetto sul 
differenziamento cardiaco, sia mediante un’analisi morfologica che di 
immunofluorescenza ed RT-PCR. 
Mediante analisi morfologica è stata calcolata la percentuale di inibizione del beating 
(presenza di cardiomiociti contrattili) al tredicesimo giorno del differenziamento 
confrontando cellule ES wild type non trattate e ES trattate con i peptidi (sia 
bloccante che di controllo) a diverse concentrazioni. L’analisi di tale risultato ha 
mostrato un’inibizione dose-dipendente del differenziamento cardiaco, soltanto nelle 
cellule trattate con il Peptide bloccante. Tali cellule non erano in grado di 
differenziare efficientemente in cardiomiociti ma assumevano un fenotipo simile a 
quello osservato nelle cellule cripto-/-, caratterizzato dalla presenza di una fitta rete di 
neuroni. Questa osservazione è stata confermata sia mediante immunofluorescenza 
utilizzando un marcatore neurale specifico (Tuj1), che analizzando il profilo di 
espressione di marcatori specifici del differenziamento cardiaco e neurale.  
Studi precedenti hanno dimostrato che le cellule ES cripto-/- differenziano 
efficientemente in neuroni ed, in particolare, in neuroni dopaminergici. Infatti, le 
cellule ES trattate con il peptide bloccante, generano un numero maggiore di neuroni 
dopaminergici, come dimostra l’incremento di cellule che risultano positive ad un 
marcatore per il fenotipo dopaminergico (TH) e dagli alti livelli di espressione non 
solo di TH, ma anche del gene che codifica il trasportatore della dopamina (DAT). 
Inoltre, Wnt1, coinvolto nella sopravvivenza e nel differenziamento dei neuroni 
dopaminergici, è overespresso nelle cellule trattate con il Peptide bloccante. Quindi, 
il Peptide bloccante non solo è in grado di indurre differenziamento neurale in cellule 
ES wild type ma anche di indurre specificamente la formazione di neuroni 
dopaminegici.  
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Inoltre, per confermare la specificità del Peptide bloccante sul differenziamento 
neurale abbiamo analizzato l’espressione di geni associati sia alla pluripotenza delle 
cellule ES (Oct3/4 e Nanog) che agli altri foglietti embrionali: mesoderma cardiaco 
(MLC2a) ed endoderma ("-foetoprotein). Sorprendentemente, sia Nanog che Oct3/4, 
espressi nella blastocisti e nelle cellule staminali pluripotenti, sembrano essere 
down-regolati nelle cellule trattate con il Peptide bloccante. Questo risultato potrebbe 
evidenziare una riduzione della presenza di cellule indifferenziate e una maggiore 
capacità delle cellule ES, trattate con il BP, di differenziare in un fenotipo cellulare, 
che in questo caso è quello neurale. Tale risultato è molto interessante soprattutto in 
prospettiva di un potenziale uso terapeutico; infatti, la presenza di cellule 
indifferenziate si associa ad un rischio maggiore nella formazione di teratomi in 
esperimenti di trapianto cellulare. 
Poiché Cripto è un gene chiave nel differenziamento cardiaco, abbiamo inoltre usato 
il marcatore specifico per la miosina cardiaca (MLC2a), che, come atteso, risulta 
essere espresso ad alti livelli nelle cellule non trattate o trattate con il peptide di 
controllo mentre mostra un’espressione ridotta in cellule trattate con il Peptide 
bloccante. Al contrario, non sono state riscontrate variazioni nell’espressione del 
marcatore per l’endoderma ("-foetoprotein), indicando, quindi, che il trattamento con 
il peptide identificato è specifico e non altera il differenziamento di questo foglietto 
embrionale.  
La capacità delle cellule ES cripto-/- di differenziare in neuroni e l’assenza di geni del 
differenziamento del mesoderma cardiaco terminale hanno portato ad ipotizzare che 
l’assenza del gene potesse essere di aiuto nell’ottenimento di popolazioni più 
omogenee, caratteristica determinante per l’utilizzo di queste cellule in terapia. Infatti, 
la maggiore preoccupazione legata al trapianto di cellule ES riguarda la formazione 
di teratomi da cellule indifferenziate presenti nella popolazione trapiantata. A questo 
proposito, è stato dimostrato che cellule ES wild type e cripto-/- trapiantate nel 
cervello di ratti Parkinsoniani riescono ad integrarsi nel tessuto e sono in grado di 
differenziare in neuroni dopaminergici e di recuperare il fenotipo. Inoltre, l’analisi 
istologica ha mostrato la presenza di teratomi nel 75% dei ratti iniettati con le cellule 
wild type, mentre l’assenza di teratomi in quelli iniettati con le cripto-/- [9]. 
Avendo  dimostrato che il Peptide bloccante è in grado di interferire efficientemente 
con il signaling di Cripto, riuscendo a bloccare il differenziamento cardiaco delle 
cellule ES wild type e a reindirizzarle verso quello neurale , come accade nelle  
cripto-/-, è possibile ipotizzare che il trattamento delle cellule ES wild type con il 
Pleptide bloccante determini una riduzione se non l’assenza di teratomi. 
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2. INTRODUCTION 
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2.1 Stem cells and regenerative medicine 
 
  Repair of damaged tissues and organs is critical for the survival of any individual. In 
general, this is accomplished through two distinct, but interdependent, processes. 
First, dead cells must be replaced by newly generated ones, and then newborn cells 
must differentiate and become organized in complex patterns that, ideally, should 
restore the original structure of the injured tissue. The repair properties of any tissue 
or organ are therefore linked primarily to its intrinsic ability of cell replacement. 
Consequently, repair is usually more efficient in tissues with a high cell turnover and 
limited need for pattern reconstruction. For example, cutaneous wounds or bone 
fractures can leave long-lasting scars, but full functional recovery is usually attained 
within a few weeks. The adult mammalian central nervous system (CNS), on the 
other hand, has weak capabilities for both endogenous cell replacement and pattern 
repair (the rewiring of specifically organized long-distance connections), both of 
which are essential to achieve a significant functional recovery. Cell transplantation 
might help us to overcome the intrinsic incapability of the nervous tissue to replace 
lost elements. In addition, grafted cells might produce some beneficials effects by 
providing host cells with trophic support. However, neural transplantation will yield 
little benefit if the donor cells fail to integrate functionally into the recipient brain 
circuitry. The potential clinical impact of cell replacement in neurological disease has 
already been shown by the transplantation of fetal mesencephalic cells into patients 
with Parkinson’s disease, which led to long-lasting symptomatic improvement in 
many treated individuals [11]. However, despite these promising results, significant 
constraints still hamper the use of fetal cells for neural transplantation. Besides the 
ethical concerns related to the use of material from aborted fetuses, its viability and 
purity cannot be reliably controlled. In addition, fetal cells are mostly postmitotic and 
cannot be expanded or stored for longer than few days, so the preparation of donor 
tissue has to be synchronized with neurosurgery within a very narrow window of time.  
The recent breakthroughs in stem cell research have opened up new possibilities for 
cell replacement therapy to treat neurological diseases [11].  
Stem cells are defined as clonogenic, self-renewing progenitor cells that can 
generate one or more specialized cell types. There are two main types of stem cells: 
embryonic and non-embryonic. Embryonic stem cells (ES) are pluripotent and can 
differentiate into a wide range of cell types under appropriated culture conditions; 
whereas, non-embryonic stem cells (non-ES) are multipotent because their potential 
to differentiate is more limited to cell types of a particular tissue, being responsible for 
organ regeneration. ES cells are more prevalent than non-ES cells and have a 
greater potential to spontaneously differentiate than non-ES cells [12]. 
Non-embryonic stem cells are also known as adult (postnatal) stem cells, since they 
derive from adult tissues, such as the bone marrow. Primitive stem cells within the  
bone marrow niche  (hematopoietic stem cell, HSC) posses functional versatility 
broader than expected ,which is termed trans-differentiation or stem cell plasticity 
[13]. Stem cell plasticity describes the ability of adult stem cells to cross lineage 
barriers and to adopt the expression profiles and functional phenotypes of cells 
unique to other tissues [14]. HSC, expressing markers of the hematopoietic lineage 
(CD45+) and of hematopoietic stem cells (CD34+), are capable of genomic 
reprogramming upon exposure to a novel environment and give rise to other tissues 
such as liver, cardiac muscle, or brain [15]. In addition to HSC, bone marrow also 
contains mesenchymal stem cells (MSCs), which have the capacity to proliferative 
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extensively and form colonies of fibroblastic cells [16]. Other adult tissue sources 
include the nose, muscle, liver, skin, brain, and the retina and limbus of the eye [17]. 
The term “non-emryonic stem cell” is also applied to less mature source of tissue 
including umbilical cord blood, obtained at birth, placenta and fetal somatic tissues 
such as pancreas and liver. Fetal tissues also provide stem cells of an embryonic 
nature; however, these can only be obtained from the gonads in the first trimester of 
development [12]. 
Finally, discovery of cancer stem cells in leukemias and solid tumors has added to 
the complexity of the stem cell field but stimulated great excitement for both stem cell 
and cancer biologists [18]. 
 
2.2 The Embryonic Stem (ES) cells 
 
  ES cells derive, both in mouse and human, from the inner cell mass (ICM) of 
preimplantation embryos at blastocysts stage [19]. ES cells can proliferate indefinitely 
in vitro as undifferentiated cells either in the presence of relatively high 
concentrations of leukemia inhibitory factor (LIF) or on the top of a layer of mitotically 
inactivated mouse embryonic fibroblasts (MEFs) [20]. They can give rise to cell 
lineages of any type of body tissues/organs, when specific stimuli and/or carefully 
chosen combination of extrinsic and intrinsic signal factors are provided in the culture 
(Fig.1). The latter property of ES cells is called pluripotency. Several transcription 
factors have been demonstrated to regulate differentiation of ES cells into specific 
cell types. Ectopic overexpression of such factors stimulates ES cells to differentiate 
selectively into specific cell types; furthermore, treatment of ES cells with factors 
such as ascorbic acid, butyric acid and DMSO also improves the differentiation of ES 
cells to specific mature phenotypes [21], [22].  
 
 
 
 18
 
 
 
 
 
 
 
Fig.1: Overview of the derivation of ES cells and their pluripotency. ES cells are 
derived from the ICM of the early blastocyst and expanded into culture. The Embryoid 
Body is an intermediate stage during in vitro differentiation of ES cells into all three 
different germ layers and their derivates. 
 
In the absence of LIF, or when removed from feeder layers and transferred into 
suspension culture, ES cells differentiate spontaneously into multicellular cell 
aggregates/ embryoid body (ESCAs/EBs), which resemble early post implantation 
embryos. Formation of EBs promotes spontaneous differentiation of ES cells into the 
three embryonic germ layers:  ectoderm, mesoderm and endoderm, eventually 
generating both embryonic and adult cell types which include: cardiomyocytes, 
hematopoietic progenitors, skeletal myocytes, smooth muscle cells, adipocytes, 
hepatocytes, chondrocytes, endothelial cells, melanocytes, neurons, glia, pancreatic 
islet cells, primitive endoderm etc. [23].  
Worth noting, the routinely used differentiation protocols give rise to a mixture of 
different cell populations. To harvest a single population of cells, several strategies 
have been developed such as the use of magnetic bead tagged antibodies or 
fluorescence labelled antibodies directed against the unique cell surface marker of 
the desired population. Some protocols employ selective culture conditions that 
promote the growth of one particular cell type at the expense of the other. ES cells 
may be genetically engineered to have selection markers or fluorescent markers 
under the control of lineage/tissue specific promoter, such as a transcription factor 
that is switched on early during lineage specific differentiation.  
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2.3 Stem-cell based therapy in Parkinson’s disease 
 
  Current research has focused on the use of stem cells to generate neural cell 
lineages for the treatment of neuronal cell loss associated with neurodegenerative 
diseases (such as Parkinson or Alzheimer), stroke or CNS injury. Various studies 
have demostrated the succesful transplantation of either stem cells or precursors into 
different experimental models of CNS injury and disease, resulting in improvements 
and/or functional recovery [24], [25], [26], [27], [28].  
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized  
at a pathological level by a progressive degeneration and loss of: (1) nigrostriatal and 
mesolimbic dopaminergic neurons, leading to tremor, rigidity and hypokinesia, the 
classical symptoms of the disease; (2) noradrenergic neurons of the locus coeruleus, 
involved in the progression of the disease; and (3) serotonergic neurons of the raphe 
obscurus and medial raphe [29]. In addition to neuronal loss, a second prominet 
feature of PD is the formation of intracellular fibrillar inclusions, called Lewy bodies, 
which consist of abnormally accumulated proteins, including "-synuclein [30]. The 
cause of the selective degeneration of specific populations of neurons in PD is 
unknown, but it has been suggested that increased oxidative stress, mitochondrial 
sysfunction, and excytotoxic damage are involved in the physiopathology of the 
disease. Current approaches for the treatment of PD include symptomatic treatment 
with combined L-DOPA and carbidopa, which increases the synthesis and release of 
dopamine [31]. 
Cell replacement strategies in PD have focused initially on the use of fetal 
mesencephalic tissue for transplantation. The success of this approach in clinical 
trials has been limited, however, by practical and ethical issue associated with the 
need for six to seven human fetuses to provide sufficient numbers of dopaminergic 
neurons for one Parkinson’s disease (PD) patient. Using fewer dopaminergic 
neurons and non-dissociated pieces of mesencephalic tissue after long-term culture 
and without immunosuppression did not show any therapeutic effect. A high number 
of dissociated dopaminergic cells are required to achieve therapeutic effects [32]. 
Grafting of tissues containing diverse types of catecholamine cells, such as 
chromaphin or carotid bodies, has been proposed as an alternative method for cell 
replacement. Other approaches have included the engineering of diverse cell types 
to produce L-DOPA and/or dopamine and the enginnering of a complete midbrain 
dopaminergic phenotype in multipotent stem/neural progenitors cells  [33]. 
Positive results with intracaudateputamen grafting of human embryonic 
mesencephalic tissue in PD patients have provided the foundation for the 
development of novel cell replacement strategies based on the grafting of neural 
stem cells [29]. Recent data have shown that Embryonic Stem (ES) cells may serve 
as a source for deriving the optimal dopaminergic (DA) cells to restore the 
nigrostriatal system [2].  
It has been shown that naive ES cells, when grafted at low concentration, develop 
into normal midbrain-like DA neurons that cause gradual and sustained behavioral 
restoration of DA-mediated motor asymmetry [2]. Worth noting, previous 
observations indicated that grafts resulting from high concentrations of ES cells often 
developed into cells originating from all germ layers giving rise to teratoma formation 
[34]; thus suggesting that application of low doses of ES cells will result in diluting 
epidermal or other germ-layer inducing signals and cell-cell contact, resulting in 
facilitating neural differentiation [2]. 
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The molecular mechanisms as well as the signaling pathways implicated in neural 
generation in the context of stem cells have not been extensively evaluated and need 
to be further characterized. Indeed, both the growth and the differentiation potential 
of ES cells need to be controlled, and the risk associated with the growth of non-
neural tissues like teratoma formation needs to be eliminated. Worth noting, many 
signaling networks that orchestrate the development of ES cells and their 
differentiation to generate functional hematopoietic, mesenchymal, and epithelial 
lineages are also implicated in various forms of human cancer. These include 
signaling pathways activated by the ligand Wnt, epidermal growth factors (EGF), 
insulin-like growth factors (IGFs), and fibroblast growth factors (FGFs). The pathways 
activated by each of these ligands regulate lineage establishment and activation of 
these pathways can contribute to tumorigenesis. Implantation of undifferentiated ES 
cells leads to formation of benign teratoma in the recipients [20]. This demands a 
pure population of terminally differentiated cell phenotype. In this respect, new 
strategies and methodologies need to be developed to isolate the terminally 
differentiated cells. For example, ES cell implants can be tagged with some kind of 
death signals in such a way that when they start to form tumors by accident, or when 
they start to cause severe complications, they will be cleared off from the body 
leaving the host unaffected [35]. Moreover, ES cell-derived cellular grafts might be 
rejected due to immunogenicity of the transplanted cells. ES cells can be easily 
manipulated genetically to overcome the problem of immune rejection so that lifelong 
pharmacologic immunosuppression will not be needed. However, although the 
therapeutical cloning approach appears to be promising for avoiding possible 
immunological problems by the recipients, this approach bears several ethical 
problems that should be solved by social consensus before clinical studies in this 
direction can be initiated [35]. 
Based on these considerations, the introduction of developmental control genes into 
stem cells may be a useful strategy to direct their differentiation and eventually 
promote controlled differentiation. Actually, the developmental fate of a cell can be 
determined by insertion or deletion of genes encoding factors that control various 
stages of development. Although this approach may represent a powerful strategy, it 
suffers from several adverse side effects due to clonal variance, promoter 
dependence and the apparent ability of some ES cells to silence the expression of 
transgenes [36]. To overcome these problems, a great effort is made at identifying 
secreted molecules capable of promoting controlled differentiation of stem cells. For 
example, a good proportion of neural differentiation is achieved by treatments of multi 
cellular aggregates derived from ES cells (Embryoid Bodies, EBs) with retinoic acid, 
in the presence of serum [37] or by co-culture of ES cells with a particular stromal cell 
line, PA6 [27]. Although these methodologies can improve the efficiency of neural cell 
generation, they both show some limits. The action of retinoic acid is pleiotropic and 
of indeterminate physiological relevance; it is therefore preferable to avoid RA 
treatment. On the other hand, the effect of PA6 cells is attributed to an undefined 
neural inducing activity; the factor(s) responsible have been termed stromal cell-
derived inducing activity (SDIA) and the nature of the factors that mediate 
neurogenesis is still unknown. 
Studies during the last decade have established that members of the transforming 
growth factor-! (TGF-!) superfamily play a critical role in cell morphogenesis and 
lineage specification in the developing brain [38]. Thus, regulation of neuronal 
growth, differentiation and specification depends on the activity of these growth and 
morphogenetic factors, their antagonists, as well as their target membrane-bound 
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receptors and intracellular signaling proteins [38]. Smad4 and Cripto encode key 
components of the TGF-!  signaling pathway that regulates multiple aspects of 
embryogenesis, including mesodermal and epidermal cell development [39] and it 
has been suggested that inhibition of these intrinsic and extrinsic signals can favor 
neuroectoderm development [38]. 
Particular attention is focused on cripto gene. Indeed, disruption of cripto in ES cells 
results in an enhanced ability of these cells to generate neurons in the absence of 
any specific inducing factors; furthermore, in vitro differentiation of cripto-/- ES cells 
results in increased dopaminergic differentiation and, upon transplantation into 
Parkinsonian rats, it results in behavioural and anatomical recovery with no tumor 
formation [9].  
2.4 Cripto and the  EGF-CFC family 
  Cripto is the original member of a family of vertebrate signaling molecules, the EGF-
CFC family, which includes: human, mouse (cripto and cryptic), chicken (cripto), 
Xenopus (FRL1) and Zebrafish (oep) [40], [41], [42], [43], [44], [45], [46]. These 
factors have key role in specific developmental processes such as anteroposterior 
(A-P) axis formation and left-right specification [47], [48], [49], [4], [50]. All EGF-CFC 
proteins contain a signal sequence for extracellular secretion, a variant Epidermal 
growth Factor (EGF)-like motif, a novel cystein-rich domain called the CFC domain 
(for cripto-FRL1-Cryptic) and a C-terminal hydrophobic region. Initially described as 
secreted molecules, members of this family are extracellular membrane proteins, 
anchored to the lipid bilayer through a glycosylphosphatidylinositol (GPI) moiety [51] 
(Fig.3).  
 
 
 
Fig.3: Schematic representation of the domains structure of the EGF-CFC proteins. 
Yellow: signal peptide; cyan: pseudo-EGF motif; violet: CFC motif; orange: hydrophobic C-
terminus. Bottom: consensus sequences of EGF-like, pseudo-EGF, CFC motifs. 
 
 
Although all the members of the family show a high level of primary sequence identity 
in two of the central motifs termed EGF-like and CFC motifs, they share a weak 
overall primary sequence identity. It is worth noting that the sequences at the N- and 
C-terminal regions of the EGF-CFC proteins are apparently unrelated. Therefore, 
based on their weak overall primary sequence identity, it has been suggested that 
Cripto, Cryptic, FRL1 and Oep define four distinct members in the EGF-CFC family 
[44] (Fig.4).  
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Fig.4: Sequence alignment of the EGF-CFC proteins: mouse Cripto (mCripto), human 
Cripto (hCripto), human Cryptic (hCryptic), mouse Cryptic (mCryptic), chicken Cripto 
(cCripto), frog FRL1 (FRL1) and zebrafish Oep (Oep). Blue and green shaded areas indicate 
the EGF and the CFC domains, respectively.  
 
The cripto cDNA encodes a protein of 171 amino-acids with a predicted molecular 
mass of 18 kDa. However, its apparent molecular weight under denaturing conditions 
is ~23 kDa, due to post-translational modifications (N- and O-glicosylation). Mouse 
Cripto is a membrane-bound protein containing two structural consensus required for 
glycosilphosphatidylinositol (GPI) anchoring to the cell membrane: a C-terminal 
hydrophobic region and a sequence matching the consensus GPI cleavage and 
attachment, consisting of a tripeptide with small amino acids in the first and third 
positions, ~30 amino acids upstream  the C-terminus of the protein. Accordingly, it 
has been shown that Cripto protein can be released from the membrane upon 
treatment with phosphatidylinositol phospholipase C (PI-PLC) [51]. Only mouse 
Cripto and Zebrafish Oep have been clearly demonstrated to be membrane-
anchored, while the subcellular localization of the other members of the EGF-CFC 
family still remains to be clarified.  
 
 
 
Hydrophobic region Signal peptide 
Overall sequence identity   22% - 32%
EGF-Like-Motif CX7CX2-3GXCX9-13CXCX3YXGXR C 
Pseudo EGF Motif 
CX4HX2WX4CX2CXCX4LXCX7-8 C D 
CCXNGGTCXLGXFCXCPX2FXGRX C 
CFC Motif 
cCripto EGF CFC 193 aa 
hCripto 188 aa 
mCripto 171 aa EGF CFC
EGF CFC
mCryptic 202 aa 
223 aa hCryptic EGF CFC
EGF CFC
xFRL1 190 aa EGF CFC
zOep 183 aa EGF CFC
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2.4.1 Signaling pathways and biochemical activity of Cripto 
 
  Cripto was originally described as an EGF-related growth factor [40]. While in the 
canonical EGF motif, three loops (A, B and C) can be recognized, the variant EGF-
like motif in the Cripto protein lacks the A loop, possesses a truncated B loop and 
has a complete C loop which results in a structure that does not bind to the EGFR 
family of receptors [52]. However, Cripto does cross-talk with ErbB4 receptor and 
FGFR-1 indirectly, stimulating the tyrosine phosphorylation of these receptors and 
contributing to the subsequent stimulation of growth [52], [3].  
Molecular genetic experiments in mice, Xenopus and Zebrafish point to a strong 
functional link between the EGF-CFC proteins and Transforming Growth Factor beta 
(TGF!)-ligand Nodal [47], [4]. In particular, mouse embryos deficient in Nodal activity 
or Zebrafish lacking the Nodal-related genes cyclop (cyc) and squint (sqt) exhibit 
defective gastrulation phenotypes very similar to those of cripto or oep mutants, 
respectively, thus suggesting that Cripto and Nodal proteins act in the same pathway 
[53], [10]. Both receptor reconstitution experiments and coimmunoprecipitation 
assays have helped to unravel the biochemical interactions of Cripto, Nodal and the 
Activin typeI serine/threonine kinase receptors (Alk4 or Alk7). Receptor reconstitution 
experiments  in Xenopus embryos have shown that Cripto interacts with Alk4 to 
permit Nodal binding to the Alk4/Activin typeII serine/threonine kinase receptor (Act-
RII) complex, leading to Smad phosphorylation [6], [54]. In addition, Cripto was 
shown to be implicated in Nodal signaling via the orphan receptor Alk7, since its 
expression enhances the ability of Alk7 and ActRIIB to respond to Nodal ligands [54]. 
Finally, a purified recombinant Cripto protein has been shown to directly bind Nodal 
as well as the Alk4 and Alk7 receptors in the absence of any coreceptor, thus 
suggesting a cooperation mechanism between these two receptors and Cripto in 
mediating Nodal signaling [55]. Interstingly, site-direct mutagenesis experiments 
demonstrated that Cripto binds to Alk4 through its CFC domain to facilitate signaling 
through the Smad pathway [6], [39]; whereas, Cripto binding to Nodal utilizes the 
EGF motif [6]. Furthermore, recent work indicate that site-specific N-glycosilation and 
O-fucosylation may be necessary for Cripto function suggesting that post-
translational modifications of Cripto could have a role in Nodal signaling regulation 
[56], [57], [58]. According to the current model, membrane-bound Cripto recruits 
Nodal to the Activin typeI  (Alk4 or Alk7) and Activin typeII receptors complex 
(ActRII); upon receptor activation, intracellular effectors Smad2 and/or Smad3 are 
phosphorylated and accumulate together with Smad4 in the nucleus to activate 
downstream target genes (Fig.5).  
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Fig.5: Schematic representation of Nodal/Cripto/Alk4/Smad signaling pathway. Cripto 
acts as a cofactor for Nodal/Alk4 to activate the downstream signaling effectors (Smads). 
 
Worth noting, it has been shown that Cripto can also block activin signaling in cell 
culture assays and it associates in vitro with activin and ActRII (or ActRIIB) to block 
assembly of an Alk4 complex [59]. It is thus  suggested that Cripto could promote 
tumorigenesis both by inhibiting the tumor suppressor activity of the Activin and by 
mediating signaling by Nodal or related TGF-! ligands [60]. 
Finally, Cripto has also been shown to activate non-TGF-! signaling pathways. 
Indeed, activation of the ras/raf/mitogen-activated protein kinase (MAPK) and 
PI3K/AKT pathways by Cripto has been demonstrated both in mouse and human 
mammary epithelial and cervical carcinoma cells; however, the relationships between 
these pathways and the Nodal pathway is still unclear [61]. 
 
2.4.2 Role of Cripto in embryo development and ES cell 
differentiation   
 
  Early studies of cripto were focused on its possible role in cell transformation and 
tumor progression. Cripto expression was first found in human and mouse embryonal 
carcinoma cells (EC) and male teratocarcinomas and it was demonstrated to be 
activated in breast, cervical, ovarian, gastric, lung, colon and pancreatic carcinomas, 
in contrast to normal tissues where cripto expression was invariably absent [3]. Cripto 
can function as an oncogene by inducing cell transformation, migration, invasion and 
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epithelial-to-mesenchimal transition (EMT) in mammary epithelial cells and in breast 
and cervical carcinomas cells [62]. EMT is one of the key processes in 
morphogenesis and tumor progression; it involves a dramatic change in cells 
phenotype by which a well-differentiated and polarized epithelial cell is converted into 
a mesenchymal cell with a leading edge that facilitates its migration through the 
extracellular matrix, and thus the colonization of different structures. Interestingly, 
acquisition of this phenotype is fundamental for the formation of many tissues and 
organs during embryonic development and constitutes the first step in the metastatic 
process in tumors of epithelial origin [63]. 
Besides its role in tumor progression, a great effort has been undertaken to unravel 
the role of cripto in development and ES cell differentiation. In mouse embryos, cripto 
is expressed early in the inner cell mass (ICM) and the throphoblast cells of the 
blastocyst. At 6.5dpc cripto is expressed in the epiblast and the primitive streak stage 
in the forming mesoderm. Later on, cripto expression is associated with the 
developing heart structures. In 8.5 dpc embryos, cripto is expressed in the 
myocardium of the developing heart tube, whereas, et 9.5 dpc its expression is 
restricted to the outflow region, conotroncus, of the heart. After 10.5 dpc, no 
expression of cripto is detected [41]. According to this expression profile, mouse 
embryos deficient for the cripto gene die around day 7.5 of embryogenesis due to 
defects of mesoderm formation and axial organization [64]. Furthermore, cripto 
mutants exhibit defects in myocardial development as evidenced by the absence of 
expression of terminal myocardial differentiation genes such as "MHC and MLC2v 
[5], [65]. These embryos consist mostly of anterior neuroectoderm and lack posterior 
structures (head without trunk). The letality of cripto-/- embryos at early stages, and 
their gross developmental abnormalities, precludes the investigation of heart 
morphogenesis in these mutants. To address the role of Cripto in the commitment 
and differentiation of the cardiac lineage, the pluripotent embryonic stem cells 
represent a suitable “in vivo-like” model to recapitulate early stages of cardiac 
development. Accordingly, by using embryoid bodies (EBs) derived from cripto-/- ES 
cells, it has been shown that cripto is essential for cardiomyocyte induction and 
differentiation [66]. Cripto-/- EBs do not generate contracting cardiomyocytes even 
during extended culture periods. Wild type (wt) and cripto-/- ES cells induced to 
differentiate by the hanging drops protocol show noticeable differences. Cripto-/- 
derived EBs give off extensive outgrowths of neuritis; in contrast, no wt-derived EBs 
show neuritic outgrowth. Accordingly, as shown by immunostaining with a pan-neural 
antibody !III-tubulin, neurons were detected in most if not all of cripto-/- EBs; 
whereas, !III-tubulin positive cells were never detected in cripto-/-  EBs treated with 
recombinant Cripto protein that, on the contrary, showed extensive areas of MF-20 
positive cardiomyocytes (Fig.7A). 
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Fig.7: Cripto promotes cardiomyocyte differentiation and inhibits neural differentiation 
of ES cells according to the timing of exposure. (A) Cardiomyocyte versus neuronal 
differentiation of cripto-/- EBs as revealed by indirect immunofluorescence. 2-d-old cripto-/- 
EBs, derived from cripto-/- cell line (DE7), were either left untreated (a and c) or treated for 24 
h with recombinant Cripto protein (b and d). On day 12 of in vitro differentiation, expression 
of either sarcomeric myosin or !III-tubulin was revealed by immunofluorescence using anti-
MF20 (red, a andb) or !III-tubulin (green, c and d) antibodies, respectively. (B) 
Cardiomyocyte versus neuronal differentiation of cripto-/- EBs-derived cells depends on the 
timing of exposure to Cripto. 
 
 
Kinetic experiments indicate that the timing of Cripto signaling required for priming 
ES cells to cardiomyocyte resembles the competence window of ES cells to acquire 
a neural fate. Indeed,  addition of effective doses of Cripto protein to cripto-/-  ES cells 
during 0-2 day interval restores cardiomyocyte differentiation and, at the same time, 
results in a dramatic inhibition of neural differentiation (Fig.8). Conversely, addition of 
recombinant Cripto protein at later time points (3-6 day interval) results in progressive 
impairment of cardiac differentiation, as well as in increased competence of cripto-/- 
ES cells to acquire a neural phenotype; thus suggesting that different timing of Cripto 
signaling induces different fates in ES cells (Fig.8).  
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Fig.8: Different timing of Nodal-dependent Cripto signaling induces different cell fates. 
Cardiomyocyte versus neuronal differentiation of cripto-/- derived EBs in the presence of 
serum. Addition of Cripto during the 0-2 days interval of differentiation results in 
cardiomyocyte induction and differentiation. Addition at later time points (3-6 days) fails to 
specify the cardiac lineage and results in neuronal differentiation. 
 
 
Stimulation of cripto-/- ES cells with recombinant Cripto has been shown to activate 
the intracellular effector Smad2. Temporal and spatial regulation of the Smad 
pathway may be important for normal cardiac development from initial cardiomyocyte 
differentiation to terminal cardiac morphogenesis. Intracellular activation of Smad2, 
upon stimulation with recombinant Cripto, require assembly of an active Activin typeI 
and typeII receptor complex. According to a functional role of Alk4 receptor in Cripto-
dependent cardiogenesis, overexpression of an activated form of Alk4 restores the 
ability of cripto-/- ES cells to differentiate into cardiomyocytes [7]. 
Thus, Cripto acts via Alk4/Nodal signalling pathway to promote cardiomyogenesis 
and impair neurogenesis in ES cells (Fig.9). 
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Fig.9: Schematic representation of Nodal-dependent Cripto signaling in cardiomyocyte 
differentiation. Nodal binds directly to Cripto, leading to the assembly of ActRII and Alk4 
followed by Alk4 phophorylation and downstream signaling. 
 
2.5 Generation of dopaminegic neurons from cripto-/-  ES 
cells 
 
  Recently, Parish C. et al. have shown that the absence of cripto promotes ES cell 
differentiation into tyrosine hydroxylase (TH) [9]. Furthermore, treatment of cripto-/- 
derived EBs with Shh and/or FGF8, two factors important for ventral midbrain 
dopaminergic (DA) neurons, strongly increases the proportion of TH-positive cells as 
well as the expression of dopaminergic transporter (DAT), compared to wild-type ES 
cells. Finally, both Wnt1 and Ret, required for survival and differentiation of DA 
neurons, are over-expressed in cripto-/- compared to wild-type EBs. Suppression of 
cripto thus allows ES cells to spontaneously differentiate into neurons, and can 
increase the cellular pool for dopaminergic differentiation. The increased neural 
induction in cripto-/- ES cells as well as the absence of at least some aspects of 
terminal mesoderm differentiation, have led to hypothesize that suppression of Cripto 
may reduce unwanted cell development, thus improving the therapeutic use of ES 
cells. Accordingly, cripto-/- ES cells, when grafted at low density, generate TH-positive 
cells able to restore behavior in an animal model of PD and, furthermore, do not lead 
to the formation of teratomas [9]. It is worth noting that transplantation of higher 
doses of cripto-/- ES cells results in generation of terminally differentiated 
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mesodermal cell types, suggesting that loss of Cripto activity could be compensated 
in transplant condition by spatial constrain and by the host mouse adult striatum [67]. 
Cripto is thus a key regulator of ES cell fate; indeed, it is strictly required in an early 
acting window to negatively regulate neural differentiation and, at the same time, to 
permit differentiation of ES cells to cardiac fate. Cripto may thus represent an 
attractive target for future therapeutic approach. 
 
2.6 Aims of the study 
  For the success of cell-based transplantation therapies in neurodegenerative 
diseases such as Parkinson Disease (PD)  the control of stem cells differentiation is 
an important goal. In this regard, Embryonic Stem (ES) cells may be an optimal 
source for deriving the dopaminergic (DA) cells to restore the nigrostriatal system. 
Recent findings indicate that the EGF-CFC protein Cripto is a key player in the 
signaling pathways that control neural differentiation of ES cells; indeed, disruption of 
cripto in ES cells results in increased dopaminergic differentiation and a reduction in 
tumor formation upon transplantation in Parkinsonian rats. 
Based on these observations, we can hypothesize that inhibition of Cripto activity by 
affecting Cripto signaling will result in the commitment of ES cells to a neural fate; 
thus improving the efficiency of generation of neurons from mammalian ES cells. The 
identification and characterization of such molecules will represent a challenging 
approach towards the understanding of the molecular mechanisms underlying neural 
induction in the contest of murine ES cells. 
The specific aims of this study are: a) to identify molecules able to inhibit 
Cripto/receptor interaction by exploiting a powerful experimental approach based on 
the use of combinatorial chemistry; b) to improve the therapeutic potential of ES cells 
for cell replacement therapy in PD. 
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3. RESULTS 
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3.1 Identification of a novel peptide that antagonizes 
Cripto/Alk4 receptor interaction 
 
  In order to identify new peptides able to inhibit the interaction between Cripto and its 
receptor Alk4, a combinatorial tetrameric tripeptide library, built with non-natural 
aminoacids (Fig.10), was previously screened. 
 
 
 
Fig.10: Schematic structure of tetrameric tripeptide library. A letter indicates the 
unknown positions. 
 
The screening was carried out by an ELISA competition assay whereby the 
displacement of recombinant Cripto from coated Alk4-receptor by the peptides was 
evaluated. The screening procedure led to the selection of a peptide that was able to 
block the interaction of Cripto and Alk4 with IC50 value of 250 nM. The Blocking 
peptide showed up to 80% of inhibition when used at a molar excess of 1.000 with 
respect to Cripto concentration (1.8*10-10M); whereas, an unrelated tetrameric 
control peptide and a dimeric control peptide did not affect Cripto/Alk4 interaction 
(Fig.11). Moreover, to determine the contribution of the tetrameric structure on 
peptide activity, the dimeric and trimeric analogues were synthesized. All the 
peptides were tested at a concentration ranging between 0.1 and 3.5 #M by ELISA-
competition assay. As shown in figure 12 the tetrameric structure showed the optimal 
activity; interestingly, the loss of a single tripeptide strand in the trimer caused a 
considerable decrease of the activity; whereas, the dimeric peptide did not show any 
antagonist activity (Fig.12).  
In order to evaluate whether the identified peptide bound Cripto or Alk4 receptor, 
both the Blocking peptide (BP) and the control peptide (CP) were coated on 
microtiter plates and the binding of both Cripto and chimeric Fc/Alk4-receptor to the 
peptides was assed by ELISA assay. As shown in Fig.13, the BP did not bind Alk4, 
but it was able to specifically bind Cripto (Fig.13). 
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Fig.11: Dose-dependent inhibition of Cripto with Alk4 by BP in competitive ELISA-
based assay. Cripto Blocking peptide (BP), dimeric (DP) and tetrameric (CP) control 
peptides were assayed at concentration ranging between 100 and 1200 nM. The results 
represent the average of three independent experiments. 
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Fig.12: Influence of sequences and tetrameric structure on peptide activity. The 
histograms report the results of ELISA-competition assays on Alk4 performed with the BP 
and a dimeric (DP) and trimeric (TP) correlated structures. 
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Fig.13: The Blocking peptide (BP) binds Cripto whereas it fails to bind the ALK4 
receptor in the ELISA-based assay. Binding assay of BP  and CP to Cripto and Alk4 
receptor. 
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 3.2 The Cripto/Alk4 blocking peptide inhibits Cripto 
signaling in ES cells 
 
  The identification of a peptide able to antagonize Cripto/Alk4 interaction may 
represent a powerful tool to control ES cell differentiation without genetic 
manipulation. 
We first asked if the BP identified was able to block Alk4-dependent Cripto signaling 
in ES cells and eventually mimic the effect of the absence of cripto. 
Indeed, previous data from our laboratory showed that Cripto was able to induce 
Smad2 phosphorylation in an ES cell-based assay, in which the effect of Cripto 
activity was studied by adding recombinant Cripto protein to cripto-/- ES cells at 
different doses. The data indicated that stimulation in trans with soluble Cripto at 
0.5µg/mL was sufficient to induce Smad2 phophorilation in 2-day old cripto-/- derived-
EBs. To directly address the above issue, we evaluated whether the Blocking 
Peptide was able to block Cripto-induced Smad2 phosphorylation. To this end, 2-day 
old cripto-/- derived-EBs were serum-starved for 3 h and then treated for 20’ min with 
recombinant soluble Cripto protein either alone or in the presence of increasing 
amount of either Blocking Peptide or control peptides (2.5 µM and 25 µM).  
Both the dimeric peptide (DP) and the tetrameric peptide (CP), unable to antagonize 
Cripto/Alk4 interaction, were used as controls. The western blot analysis showed 
that, both control peptides did not have any significant effect on Smad2 
phophorylation induced by Cripto (Fig.14, Blue and green bars). On the contrary,  
when stimulation with Cripto occurred in the presence of the Blocking peptide, a 
dose-dependent inhibition of Smad2 phosphorylation was observed. Worth noting, 
when used at 25 µM, the Blocking peptide completely blocked Cripto signaling 
(Fig.14, Pink bars) and P-Smad2 levels were comparable to the untreated cripto-/- 
derived EBs (Fig.14, black bar). These data demostrate that the Blocking peptide 
was able to specifically inhibit Cripto-induced Smad-2 phosphorilation and open the 
way to evaluate its effect on ES cell differentiation. 
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 Fig14.: Inhibition of Cripto-induced Smad2 phosphorilation on Cripto-/- ES cells 
The selected peptides, in combination with recombinant mouse Cripto, were used in the 
cripto-/- ES cell differentiation to test their ability to inhibit Cripto-induced Smad2 
phosphorilation. The peptides and recombinant mouse Cripto were added directly to 2 
day-old ES cell-derived EBs for 20 minutes. Dimeric (DP) and tetrameric (CP) forms were 
used as negative controls .  
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3.3 Cripto Blocking peptide is able to impair 
cardiomyogenesis and to redirect the neural fate of ES 
cells 
 
  The availability of molecule(s) that antagonize Cripto activity may represent a 
powerful tool to dissect the functional role of Cripto in ES cells differentiation, thus 
allowing to unravel the functional role of Cripto in the commitment of ES cells to 
neural fate. Based on these considerations and previous results, the Blocking peptide 
was used on wild type ES cells to test its ability to inhibit endogenous Cripto signaling 
and thus impair cardiomyogenesis and induce neurogenesis in ES cells.  
We have previuosly identified the precise time window of Cripto signaling which is 
required to achieve proper cardiomyogenesis. Indeed, Cripto signaling is required in 
an early and narrow window (0-4 day) to promote cardiomyogenesis. 
We thus evaluated the effects of Cripto BP on cardiomyogenesis by adding both the 
BP and the CP at different time during wild type ES cell differentiation. The biological 
effect of the peptides was first evaluated by morphological analysis and the numbers 
of EBs containing beating ares was scored from day 8 to 12 of differentiation. 
We then went on to define both the optimal concentrations of the peptides and timing 
of addition. First of all, since the peptides were dissolved in DMSO, it was mandatory 
to determine the optimal DMSO concentration to be used. It is well known that DMSO 
at 1% is a potent inducer of cardiac differentiation of ES cells. For this reason, we 
have used 0.5% DMSO that, in our experimental conditions, was unable to increase 
cardiac differentiation. Addition of increasing amount (5 µM to 25 µM) of either BP or 
CPs to wild type EBs at 0-d, 0-2-d, 0-4-d of differentiation resulted (Blue arrows, 
fig.15) in severe defects of adesion and impaired differentiation. Worth noting, 
addition of peptides to EBs at 4-d of differentiation (Red arrow, fig.15) did not effect 
cardiomyogenesis. On the contrary, addition of peptides to either 2-d or 2-4-d of 
differentiation did not affect EBs adhesion and specifically impaired 
cardiomyogenesis (Green arrows, fig.15). 
 
 
 
 
0 2 4 13 Day 
 
 
Fig.15: Schematic representation of peptide addition.  Wild type ES cells were treated 
with the peptides (BP and CPs) for the indicated periods of time. Blue arrows: peptides 
addition at: 0-d , 0-2 and 0-4 day of differentiation. Green arrows: peptides addition at 2-d 
and 2-4 day of differentiation. Red arrow: peptides addition at 4-d of differentiation. 
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Interestingly, a dose-dependent inhibition of cardiomyogenesis was observed in 13- 
ay old EBs treated, with Blocking peptide (BP), at day 2 of differentiation, as shown 
 rule out the possibility of a more general effect of  the Blocking peptide on ES cell 
ifferentiation and/or viability, the effect of peptides was verified on neuronal 
d
by progressive decrease of wt EBs showing rhytmically contracting areas (Fig.16). 
On the contrary, the tetrameric control peptide did not significantly affect 
cardiomyogenesis, even if used at the highest concentrations (12,5 µM and 25 µM) 
(Fig.16). 
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Fig.16: Effect of BP on cardiomyocytes formation.  Wild type ES cells were treated or 
untreated both with BP or CP as indicated, and the percentage of beating EBs was 
 
 
 
 scored. The peptide were added raging 5 µM and 25 µM.  
   
 
To
d
differentiation of ES cells. Indeed, as previously discussed, in the absence of Cripto 
ES cells spontaneously differentiate into neurons and the competence window of ES 
cells to acquire a neural fate correlates with the timing of Cripto signaling required for 
priming cardiomyogenesis [7]. For this reason, it was hypothesised that the Blocking 
peptide, if specific and effective, could re-direct ES cell fate and promote 
neurogenesis. To evaluate whether the BP was able to promote neural differentiation 
in ES, cells 2-day old wild type EBs were treated with 25 µM of either Blocking 
peptide or tetrameric control peptide. Interestingly, when wild type EBs treated with 
Blocking peptide, were plated onto an adhesive substrate, a population of cells with a 
neuron-like morphology was observed at day 13 of differentiation. This characteristic 
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morphology was never observed either in wild type EBs or in wild type EBs treated 
with control peptide. To confirm that those cells were indeed neurons, 
immunofluorescence analysis (IF) was performed by using antibodies that recognize 
the neuron-specific form of class !III tubulin (Tuj1). To better define the activity of the 
Blocking peptide we have arbitrarily chosen four grades of neuronal differentiation on 
the basis of areas of Tuj1-ir (immunoreactive) cells (Fig.17A), ranging from the 
absence of neuronal differentiation (Grade 0) to full neuronal differentiation (Grade 3) 
where an extensive ares of Tuj1-ir cells surrounded the EBs.  The presence of either 
few isolated neurons or small areas of Tuj1-ir cells defined intermediate phenotypes, 
Grade 1 and Grade 2, respectively. 
Immunofluorescence analysis, obtained from three independent experiments, clearly 
indicated that treatment of ES cells with Blocking peptide induced extensive neuronal 
ative RT-
n, we questioned if the Blocking peptide was 
nergic (DA) 
king peptide. 
 associated both with pluripotency of ES 
2a (MLC2a). As expected, 
differentiation, showing Grade 3 phenotype in about 50% of the EBs scored. On the 
contrary, EBs treated with control peptides failed to efficiently differentiate into 
neurons, as shown by the presence of small, if any, areas of Tuj1-ir cells (Fig.17B); 
accordingly, most of the EBs showed a Grade 0 phenotype, thus confirming the 
specific effect of the Blocking peptide in promoting neuronal differentiation. 
To support the morphological as well as the IF analysis, we have evaluated the 
expression profile of both neuronal and cardiac markers by semiquantit
PCR, on RNAs extracted from 13 days-old EBs treated with either control, Blocking 
peptide, or treated with DMSO alone.  
Having shown that cripto deficiency promotes the differentiation of neurons but 
impairs the cardiomyocyte differentiatio
able to redirect specifically the differentiation to neural fate and what kinds of neuron 
subtypes were generated. We first analyzed the expression of the pan-neural NFM 
marker which clearly increased in EBs treated with the Blocking peptide.  
Furthermore, the expression of both the tyrosine hydroxylase (TH) which is a gene 
relevant to the catecholaminergic and especially to the midbrain dopami
neuronal phenotype as well as of DA transporter (DAT), which is turned on late in DA 
cell differentiation, were significantly increased upon treatment with BP. 
RT-PCR analysis also revealed that Wnt1 mRNA, required for survival and 
differentiation of DA neurons, is over-expressed in EBs treated with Bloc
All together these data indicate that the Blocking peptide not only incresed the 
capacity to generate neurons but can also generate increased numbers of DA 
neurons; furthermore, increased Wnt1 expression levels, may result in proliferation 
and terminal differentiation of DA neurons. 
Furthermore, to asses the specificity of the Blocking peptide on neural differentiation, 
we also analyzed the expression of genes
cells and the two others germ layers (mesoderm and endoderm) (Fig.18). To this 
end, we evaluated the expression profile of Oct3/4, Nanog, MLC2a and "-
foetoprotein. Oct3/4, a member of the POU family of transcription factors, and 
Nanog, an NK-2 class homeobox transcription factor, are expressed in the inner cell 
mass of blastocyst and in pluripotent stem cells, and they are down-regulated upon 
ES cell differentiation [68], [69]. In this experiment, both Oct3/4 and Nanog appeared 
down-regulated in EBs treated with the Blocking peptide.  
Since Cripto has a key role during cardiac mesoderm formation, we used a specific 
marker gene for cardiomyocytes, the myosin light chain 
MLC2a was expressed at higher levels both in untreated EBs and EBs treated with 
control peptide, and was down-regulated in EBs treated with the Blocking peptide. 
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On the contrary, expression levels of the endoderm-specific marker "-foetoprotein, 
were comparable in both BP and CP treated EBs. 
The increased neural induction in wild type EBs treated with the Blocking peptide as 
well as the absence of at least some aspects of terminal cardiac differentiation have 
led to hypothesize that suppression of Cripto may reduce unwanted cell 
development, thus improving the therapeutic use of ES cells. 
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increases the number of dopamine cells by increasing neuronal precursors. 
Polymerase chain reaction showed: upregulation of NFM, TH, Wnt1 and DAT in EBs 
treated with BP; downregulation of Oct3/4, Nanog and Mlc2a in EBs treated with BP; no 
alteration of "-foetoprotein expression. !-tubulin was used as housekeeping gene 
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 3.4 Treatment of ES cells with Blocking peptide increases 
DA cells 
 
  To establish whether blocking Alk4/Smad2 dependent Cripto signaling would 
enhance the potential of ES cells to generate dopaminergic neurons, the peptides 
were used in 14day mouse ES cells dopaminegic differentiation protocol [70].  
Briefly, with this protocol the cells were plated al low density onto stromal cells (PA6) 
for a period of 5 days. Cultures are then exposed to Shh and FGF-8 to push cells 
towards a DA fate for 3 days and then a further 3 days in the presence of Shh, FGF-8 
and bFGF to induce differentiation and expand the pool of DA cells. During 1-11 days 
of differentiation, the Blocking peptide and the control peptides were added every two 
days at a concentration of 12,5µM. The analysis was performed by 
immunofluorescence on 14-day old spheres generated by this protocol using both a 
specific pan-neural marker (Tuj1) and a dopaminergic specific (TH) marker 
(Fig.19A). Following the differentiation protocol treatment of ES cells with Blocking 
peptide, but not control peptides, increased the percentage of Tuj1 per sphere 
(Fig.19B) and, furthermore, the percentage of TH per sphere (Fig.19C). 
The data provide, for the first time in our knowledge, direct evidence that a 
Cripto/Alk4 Blocking peptide is a potent inducer of dopaminergic differentiation. 
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Fig.19: Effects of Cripto Blocking peptide on Dopaminergic Differentiation. Treatment 
of wild type ES cells with the BP, following the 14 day differentiation protocol, increased the 
%Tuj+spheres and % of TH/spheres. The actions of the BP on TH+ cells were predominantly 
a result of incresed neural induction (as reflected in %TH/Tuj). Additionally, the BP incresed 
the number of TH cells per spehere: 5fold increse in TH cells/sphere under optimal BP 
conditions). 
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4. DISCUSSION 
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  In this study we have used the ES cells as a source for obtaining midbrain DA 
neurons and to eventually improve the use of stem cell-based therapy in rat models 
of Parkinson’s disease. Although the ES cells differentiate into functional DA neurons 
[2], they also generate cells of the other germ layers, thus eventually giving rise to 
teratomas. Because teratoma formation is the expected outcome of transplanted wild 
type ES cells [71], reducing the capacity for both ES cells or neural precursors to 
differentiate into non-neural tissue is desirable for therapeutic neuronal grafts both to 
optimize functional effects and to limit cell overgrowth [2]. To overcome this limitation, 
a great effort is made to get insight into the molecular mechanisms which underlay 
neural induction in ES cells, an issue which is still debated in the literature. 
Based on recent findings from our laboratory, showing that disruption of cripto in ES 
cells redirects the differentiation to a neural fate and especially increases 
dopaminergic differentiation [9], we verified the hypothesis that neural induction in ES 
cells can be achieved by inhibiting Alk4-dependent Cripto signaling. Our results show 
that Cripto signaling inhibition is sufficient to induce development of neural cells and, 
moreover, that the cell population obtained lack some aspects of terminal cardiac 
mesoderm differentiation. 
4.1 The role of Cripto and the default pathway of neural 
induction 
 
  In several animal models, such as Xenopus, zebrafish, chick, and more recently in 
the mouse, a default mechanism of neural induction has been proposed [38]. This 
model proposes that neural induction is initiated by the inhibition of BMP signaling in 
the embryonic ectoderm, through the normal activity of BMP inhibitors such as 
noggin, chordin, follistatin, and twisted gastrulation.  In mammals, two lines of 
evidence are consistent with the model of neural induction using mouse ES as model 
system: first, transplantation at low density of mouse ES cells into the striatum or 
under the kidney capsule of adult mice predominantly leads to the formation of neural 
(mid and hindbrain) cell types [34]; second, in vitro differentiation of mouse ES cells 
on stromal feeders [27] or in limiting dilution assays [72] results in development of 
neural cell populations. In these experiments, the ES cells rapidly acquire a neural 
cell fate when differentiated at low cell density and/or when BMP signaling is inhibited 
by BMP antagonists. However, these experiments were based on the generation of 
neural precursors form ES cells in the absence of Embryoid Bodies (EBs) formation; 
therefore, preventing early cell-cell contact and a cellular environment for the germ 
layer development. During my phD project I have evaluated whether Cripto signaling 
inhibition is sufficient to induce neural differentiation, even in the presence of germ 
layer formation and cell-cell contact. Our data indicate that blocking Cripto signaling 
increases neurogenesis and, furthermore, ES cells do not differentiate into 
multilineage cell types; thus supporting a default model of neural induction in 
mammals 
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4.2 Cripto/Alk4 antagonists redirect the neural fate of ES 
cells 
 
  Based on previous observations that Cripto acts as a molecular switch in ES cell 
differentiation through Alk4 receptor,  we hypothesized that inhibition of Cripto activity 
by affecting Cripto-Alk4 receptor interaction would result in the commitment of ES 
cells to a neural fate, thus improving the efficiency of generation of neurons from 
mammalian ES cells. The identification and characterization of such molecules 
represent a challenging approach towards the understanding of the molecular 
mechanisms underlying neural induction in the contest of murine ES cells. 
Our aim  was to use small molecules, such as peptides, able to inhibit Cripto-Alk4 
interaction in vitro, using an ELISA-based assay. To this end, we have exploited a 
novel experimental approach based on the use of combinatorial peptide chemistry 
combined to ES cell differentiation. Peptide libraries have been largely employed to 
select new active molecules. Starting from 1990, the selection of ligands from 
combinatorial libraries has determined a revolution in molecular research and drug 
discovery [73]. The power of combinatorial selection is the design of high-affinity 
ligands for the analysis and manipulation of biochemical interaction. Among the wide 
spectrum of opportunity offered by the combinatorial approaches, the peptide 
libraries represents one of the most utilized. This is due to the numerous advantages 
that combinatorial peptide libraries offer: the synthesis is completely automated and 
with few synthetic steps a high number of molecules are obtained; the products of 
synthesis are highly homogeneous and easy to characterize [74]. 
Using recombinant Alk4 receptor and Cripto protein we have set up an in vitro 
ELISA-based assay that was used to screen a tetrameric tripeptide library composed 
of 27.000 molecules made of non natural aminoacids. Following library deconvolution 
a peptide was identified which is capable to efficiently inhibit the binding activity of 
Cripto to Alk4. This peptide, named Blocking peptide (BP), specifically binds Cripto 
whereas it fails to bind the Alk4 receptor in the ELISA-based assay. The observed 
activity was closely dependent on the aminoacidic sequence; in fact, the substitution 
of a single aminoacid with alanine caused the loss of inhibitory activity, as verified by 
Ala-scanning experiment (data not shown). Moreover, the activity of the BP was also 
structure-dependent; infact, the tetrameric structure show the optimal inhibition 
compared with dimeric and trimeric structures. 
According to its activity as Cripto/Alk4 receptor antagonist, the BP is able to block 
Cripto-induced Smad2 phosphorilation in ES cells and thus to interfere with Cripto 
signaling. Nodal/Cripto-dependent Smad2 activation is required for cardiac 
mesoderm induction, and once this pathway is inhibited, in early stage of wild type 
ES cell differentiation, neuroectodermal induction is achieved, consistent with the 
“default pathway” model [75].  
The availability of a molecule that antagonize Cripto activity may represent a 
powerful tool to dissect the functional role of Cripto in ES cell differentiation, thus 
allowing to unravel the functional role of Cripto in the commitment of ES cells to a 
neural fate. Indeed, it conceivable that if specific, enough active and non-toxic, this 
molecule, by inhibiting the endogenous Cripto activity, will induce neural 
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differentiation of wild type ES cells and may be used to develop methods to improve 
the generation of neurons from ES cells.  
According to our hypothesis, we have shown that the BP is able to mimic the 
absence of cripto in ES cells and that treatment of wild type ES cells with the BP 
results in a phenotype which resembles the cripto-/- phenotype. Infact, addition of BP 
to wild type ES cells efficiently blocks cardiomyogenesis and redirects the 
differentiation of ES cells to a neural fate. Interestingly, only the cells treated with the 
Blocking peptide efficiently differentiate into neurons as shown by the overexpression 
of the pan-neural marker (NFM), as well as the increased percentage of Tuj1 (neural 
marker) positive cells. Worth noting, suppression of cripto can also increase the 
cellular pool for dopaminergic differentiation [9]. Like cripto-/- ES cells, the wild type 
ES cells, treated with Blocking peptide, are able to differentiate efficiently into 
dopaminergic neurons and show a great percentage of TH positive cells and a high 
level of TH mRNA. Also Wnt1, a gene required for survival and differentiation of DA 
neurons, is over-expressed in EBs treated with Blocking peptide, similary to what 
observed in cripto-/- derived EBs.   
Thus, the BP-treated ES cells not only have increased capacity to generate neurons 
but can also generate increased numbers of dopaminergic neurons. At the same 
time, as expected, the cardiac fate determination is impaired, as confirmed by both 
morphological analysis and RT-PCR, which show the down-regulation of cardiac 
specific markers. Surprisingly, Oct3/4 and Nanog, both expressed in the inner cell 
mass of the blastocyst and in pluripotent stem cells, appear down-regulated in EBs 
treated with Blocking peptide. These results highlight a reduction in the number of 
undifferentiated cells eventually persisting following the differentiation protocol that 
we used. 
The increased neural induction in cripto-/- ES as well as the absence of at least some 
aspects of terminal mesoderm differentiation, have led to hypothesize that 
suppression of Cripto may reduce unwanted cell development, thus improving the 
therapeutic use of ES cells.  
One of the greatest tribulations that exists for ES cell replacement therapy, is the 
development of teratomas from undifferentiated ES cells present within the grafted 
population. In this regard, Cripto is known to be overexpressed in several tumors 
[60], [76], [77]. Grafting studies of ES cells (wild type and cripto-/-) into an animal 
model of Parkinson’s disease showed that both wild type and cripto-/- ES cells 
resulted in behavioral improvements in lesioned rats and integration of DA cells 
throughout the striatum (graft site). More importantingly, these studies demontrated 
that cripto-/- ES cell grafted animals did not show tumor formations, whilst 75% of 
brains grafted with wild type ES cells showed teratoma formation [9].  
Encouraged by our results, showing that treatment of ES cells with the BP promotes 
dopaminergic differentiation and reduces the percentage of undifferentiated ES cells,  
in collaboration with the group directed by Dr. Ernest Arenas at Karolinska Institute, 
we are currently testing the effects of BP on a rat model of PD. We hypothesize that 
the treatment of ES cells with the BP, prior to transplantation, would block Cripto 
signaling and thus reduce the risk of teratoma formation. 
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5. MATERIAL AND METHODS 
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5.1 ELISA binding and competition assay 
 
  The Alk4 receptor (R&D Systems) was adsorbed to 96 microtiter plates (10 ng/well) 
and incubated over-night at room temperature(RT). After blocking of aspecific sites 
with 180 !l/well of 1% BSA solution, 20 ng of Cripto-His protein (purified from 
conditioned medium of Cripto-His over-expressed HEK293 cells) was added in a 
volume of 100  !l/well in PBS-EDTA-Tween buffer and the plate was incubated for 1h 
at 37°C followed by 1h at RT. The plate was then incubated with 600 ng/well of IgG 
anti-Cripro-His (purified from serum of immunized rabbits) for 1h at 37°C and 1h at 
RT. A diluition 1:1000 of anti-rabbit immunoglobulin G conjugated with horseradish 
peroxidase (DAKO), was added to the plate (100 !l/well) and further incubated for 1h 
at RT. Finally, the plate was developed with o-phenylendiammine peroxidase 
substrate (Sigma Aldrich) and the absorbance was readed at 490 nm on a microtiter 
rearder (Biorad Benchmark). 
The dose dependent activity of the peptides, was measured following the above 
described protocol at concentrations reported in the Results . 
 
5.2 Propagation and maintenance of ES cells 
 
  The ES cell lines RI and cripto-/- DE7 were used throught the study [65]. Wild type 
and cripto-/- ES cells were maintained in the undifferentiated state by culture on 
mitomycin C-treated mouse embryonic fibroblast (MEF) feeder layers, according to 
standard protocols [78]. The culture medium consists of high glucose Dulbecco’s 
modified Eagle’s medium (Invitrogen, Carlsband, CA) containing 15% fetal bovine 
serum (Hyclone, Logan, UT), 0.1 mM !-mercaptoethanol (Sigma-Aldrich, St. Louis), 1 
mM sodium pyruvate (GIBCO), 1X non essential amminoacids (GIBCO), 2 mM 
glutamine (GIBCO), 100U/ml penicillin/streptomycin (GIBCO) and 103 U/ml leukemia 
inhibitory factor (LIF) (Chemicon International, Temecula, CA). ES cells were 
routinely passaged every 2 days, and the medium was changed on alternated days.  
 
 
5.3 ES cell in vitro differentiation 
 
  For in vitro differentiation to cardiomyocytes, ES cells were cultivated in embryoid 
bodies essentially as described [79], [80] and following the protocol schematised in 
Figure 20. Briefly, 400 cells in 20 #l culture medium without LIF were placed on the 
lids of tissue culture dishes filled with PBS and cultivated in hanging drops for 2 days. 
After further 3 days of culture in bacteriological Petri dishes in culture medium without 
LIF, the 5 day-old EBs were plated separately onto gelatin-coated 48-well plates for 
morphological analysis or onto 100 mm tissue culture plates for RT-PCR and 
Western blot analysis. Rhythmic beating of the EBs, indicating cardiac muscle 
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differentiation, was monitored starting to day 7 of differentiation, using phase 
microscopy (DMIRB, Leica Microsystems, Wetzelar, DE). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 20: Schematic representation of the experimental protocol used for ES cell 
differentiation into cardiomyocytes (adapted from Maltsev et al., 1993). 
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5.4 Western Blotting  
 
  For cell lysates, the EBs were collected at the indicated time, spin at 900 rpm for 5 
min to remove cell debris and lysed in 2x Laemli buffer.  Equal amounts of protein, 
defined by Coomassie staining, were suspended in 2x Laemli buffer and boiled for 5 
min. 50µg of cell lysates were resolved on (5-12.5%) SDS-polyacrylamide gel 
electrophoresis (PAGE). Gels were transferred to a PVDF membrane (Amersham, 
Buckinghamshire, UK), blocked with 5% milk in Tris-buffered saline tween (TBST) 
buffer and incubated with primary antibody overnight. After washing three times with 
TBST buffer, blots were incubated with secondary antibody in TBST-5% milk. The 
blots were then washed three times with TBST buffer and three times with TBS buffer 
before color development with ECL substrate colorimetric method (PIERCE), 
following manufacture instructions. 
Rabbit polyclonal anti-Smad2/3, anti-phospho-Smad2 (Ser465/467) (Cell Signaling) 
were used according to the manufacturer’s instructions. 
                            
5.5 ES cell in vitro differentiation and peptides treatment 
 
  ES cell differentiation was induced allowing the formation of multicellular three-
dimensional EB structures as described in Figure 20. The hanging drop culture assay 
[80] for cardiomyocyte differentiation was used throughout the study. Two day-old  
EBs were treated with increasing amounts of both Blocking peptide (5, 6.25, 12.5 and 
25 µM) and Control peptide (12.5 and 25µM) and then cultured for the remaining 
days. The number of EBs containing beating areas was scored at day 13 of 
differentiation and monitored using phase microscopy (Leica). 
5.6 Immunofluorescence  
 
  Adherent 13-day old EBs were fixed for 30’ at R.T. in 4% parafolmaldehyde in 
phosphate-buffered saline (PBS). After fixation, EBs were washed 3 times with 1X 
PBS for 5’ and then incubated with 10% normal goat serum (Dako Cytomation, 
Glostrup, Denmark)/1% BSA/0.1% Triton X-100 in 1X PBS for 15’ at room 
temperature. The EBs were then washed 3 times in 1X PBS for 5 min and incubated 
with primary antibody in 10% normal goat serum/1% BSA/1X PBS at the following 
working dilutions: monoclonal anti-!III-tubulin (1:400; Sigma-Aldrich). Following 
primary antibody incubation, EBs were rinsed 3 times in 1X PBS and further 
incubated with secondary antibodies: goat anti-mouse IgG FITC-conjugated (1:35; 
DAKO) in 1% BSA/1X PBS for 1h at RT. Finally, EBs were washed 4 times in 1X 
PBS, counterstained and mounted in VectaShield medium with DAPI (Vector 
Laboratories). Labeling was visualized by fluorescent illumination using an inverted 
microscope (DMIRB, Leica Microsystems, Wetzelar, DE); images were acquired on a 
DC 350 FX camera (Leica). 
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5.7 RNA preparation and RT-PCR 
 
  Total RNA from 13 day-old  wild type EBs treated with 25µM of either blocking 
peptide or control peptide or treated with 0.5% DMSO as control, was extracted using 
Trizol ultra pure reagent (Invitrogen), according to the manufacturer’s instructions. 
Total RNA (2 #g) was reverse transcribed with QuantiTect Reverse Transcription Kit 
(Quiagen). cDNA samples synthesized from 100ng of total RNA were subjected to 
PCR amplification with appropiate primers.  
The PCR was carried out using standard protocols: Taq polymerase (0.1 U/reaction, 
Euroclone, Pero, Italy), Reaction buffer (1X, Euroclone), MgCl2 (1.5 mM, Euroclone), 
dNTPs (0.2 mM, Euroclone). Cycling parameters were as follows: denaturation at 
94°C for 45 sec, annealing at 56°C for 45 sec and elongation at 72°C for 45 sec. The 
number of cycles was chosen to select PCR conditions on the linear portion of the 
reaction curve avoiding “saturation effects” of PCR. Primer sequences, number of 
cycles and the length of the amplified products are shown in table1.  
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Gene 
Cycle 
number Primer (sense) Primer (antisense) 
Product 
size 
Oct3/4 26 tcagcttgggctagagaagg tgacgggaacagagggaaag 250 
MLC2a 28 cagacctgaaggagacctattccc gtcagcgtaaacagttgctctacc 300 
"-
foetoprotein$ 30 ccacgttagattcctcccagtgcgt catacttgttagagagttccgtctc 200 
NFM 32 gaaatggaagaaaccctcaca ccggccttggcctctggttttgg 474 
TH 30 tgtcacgtccccaaggttcat gggcaggccgggtctctaagt 276 
DAT 30 gtgggcttcactgtcatcctca cccaggtcatcaatgccacga 514 
Wnt1 30 acctgttgacggattccaag tcatgaggaagcgtaggtcc 462 
!-tubulin$ 28 gggaggtgataagcgatgaa cccaggttctagatccacca 150 
 
 
 
Table1: Marker genes used for RT-PCR analysis 
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1. Ponticelli S., Marasco D., Lonardo E., Persico G., Ruvo M., De Falco S., 
Minchiotti G. “A combinatorial approach to identify inhibitors of the 
oncodevelopmental factor Cripto” VI Meeting of Molecular Oncology. 
Molecular Oncology group, SIC. Positano, May 9-12, 2005. 
 
2. Lonardo E., Ponticelli S., Marasco* D., Saporito* A., Ruvo* M., De Falco S., 
Minchiotti G. "A combinatorial approach to direct neuronal fate 
specification from embryonic stem cells”. 2nd Eurostemcell Summer 
School, Hydra (Greece), 14 –21 September 2006. 
“Recent breakthroughs in stem cell research underscore the importance of 
controlling stem cell differentiation for the success of cell-based therapies. In 
this perspective, recent findings from our laboratory indicate that the EGF-CFC 
protein Cripto is a key player in the signaling pathways that control neural 
induction in ES cells. Indeed, disruption of cripto in ES cells results in an 
enhanced ability to generate neurons in the absence of any specific inducing 
factors. We are exploiting a novel experimental approach based on the use of 
combinatorial chemistry combined to ES cell differentiation, to identify 
antagonists of Cripto/receptor interaction as new tools to direct neuronal fate 
specification from mouse ES cells. By using an in vitro ELISA-based 
technology, we have we have screened a tetrameric tripeptide library and 
identified peptides that are able to inhibit Cripto/ receptor interaction and are 
currently tested on ES cell differentiation assays. These molecules will be 
extremely useful to direct ES cell fate specification without the need to 
manipulate the cells genetically and may thus permit a direct extension of this 
strategy to human cells.” 
 
3. Lonardo E., Ponticelli S., Marasco* D., Saporito* A., Ruvo* M., De Falco S., 
Minchiotti G. “A combinatorial approach to direct neuronal fate 
specification from embryonic stem cells”.  
8th FISV, Riva del Garda, 28 September-1 October 2006. “Recent 
breakthroughs in stem cell research underscore the importance of controlling 
stem cell differentiation for the success of cell-based therapies. In this 
perspective, recent findings from our laboratory indicate that the EGF-CFC 
protein Cripto is a key player in the signaling pathways that control neural 
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induction in ES cells. Indeed, disruption of cripto in ES cells results in an 
enhanced ability to generate neurons in the absence of any specific inducing 
factors. We are exploiting a novel experimental approach based on the use of 
combinatorial chemistry combined to ES cell differentiation, to identify 
antagonists of Cripto/receptor interaction as new tools to direct neuronal fate 
specification from mouse ES cells. By using an in vitro ELISA-based 
technology, we have we have screened a tetrameric tripeptide library and 
identified peptides that are able to inhibit Cripto/ receptor interaction and are 
currently tested on ES cell differentiation assays. These molecules will be 
extremely useful to direct ES cell fate specification without the need to 
manipulate the cells genetically and may thus permit a direct extension of this 
strategy to human cells. 
 
4. D’Aniello C., Lonardo E., Guardiola O., Liguoro A., Liguori G. and Minchiotti 
G. “Cripto signaling in ES cell differentiation: convergent pathways in 
stem cells and tumorigenesis”. 8th FISV, Riva del Garda, 28 September-1 
October 2006.  
“During the pathogenesis of cancer, tumor cells revert to an embryonic- like 
state, where cells divide rapidly and migrate inappropriately through the body. 
Thus, by studying the interface between normal embryo development and 
tumor biology, one may gain a better understanding of the molecular events 
responsible for cancer. In this scenario, the cripto gene, the founder member 
of the EGF-CFC family has a crucial role. Cripto is expressed both in the 
Embryonic Stem (ES) cells and during the early phases of embryo 
development while, in the adult, it is reactivated in a wide range of epithelial 
cancers. The involvement of Cripto in physiological events associated with 
development and pathological events linked to tumorigenesis, points out for 
the search of genes regulated by Cripto. We have studied the expression 
profile of cripto-/- ES cells stimulated with Cripto protein for 24 hours, by using 
microarray technology. We are currently characterising the most promising 
genes by analyzing their expression profile during both ES cell differentiation 
and mouse embryogenesis. 
5. Lonardo E., D’Aniello C., Guardiola O., Autiero* M., Liguoro A., Liguori G., 
Carmeliet* P. and Minchiotti G. “Cripto signaling in Embryonic Stem cell 
differentiation: convergent pathways in stem cells and tumorigenesis. 
EMBO/IGB Workshop: “Cell migration, Tissue Invasion and Disease”, Capri, 
14-17 October 2006. 
“In the last years single molecular players of cell migration have been 
identified and their activity has resulted to be fundamental in the physiological 
embryonic development and adult life; thus defining an integrated network of 
molecules and mechanisms that are involved in the control of cell migration 
both in the embryonic and adult life. In this scenario, the cripto gene, the 
founder member of the EGF-CFC family has a crucial role. Cripto is expressed 
both in the Embryonic Stem (ES) cells and during the early phases of embryo 
development while, in the adult, it is reactivated in a wide range of epithelial 
cancers, including breast, stomach and colon carcinoma. The involvement of 
Cripto in physiological events associated with development and pathological 
events linked to tumorigenesis, points out for the search of genes regulated by 
Cripto, as a powerful approach to unravel the complex network of molecules 
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that are active during early embryogenesis and tumorigenesis. To this end, we 
have studied the expression profile of cripto-/- ES cells stimulated with Cripto 
protein for 24 hours, by using microarray technology. Indeed, because in vitro 
differentiation of embryonic cells proceeds as a developmental continuum, this 
could be considered as a powerful model system to identify key regulators of 
early embriogenesis. We are currently characterising the most promising 
genes by analyzing their expression profile during both ES cell differentiation 
and mouse embryogenesis and eventually by studying their functional 
interaction with Cripto. “ 
 
6. Guardiola O., Lafuste P.,. Lonardo E, Chevron P., Carton A., Moons L., 
Carmeliet P.and Minchiotti G. “Unraveling the role of EGF-CFC Cripto in 
muscle regeneration” VIB 2007, Leuven Belgium 
“Skeletal muscle has a remarkable regenerative capacity, but any impairment 
in the restoration of contractile properties after injury can lead to prolonged 
functional disability. The engineering of skeletal muscle tissue still remains a 
challenge. Recent findings emerging from different research fields are 
reinforcing the idea that the same molecules and mechanisms operate during 
embryonic development and in the adult, under both physiological and 
pathological conditions. 
Cripto is the original member of the EGF-CFC family, which is expressed 
during early embryogenesis as an important co-receptor for Nodal. Recently, a 
main effort has been undertaken to identify both the receptors interacting with 
Cripto and the signaling pathway activated by this interaction. Genetic 
experiments as well as biochemical approaches, defined a nodal/ALK4/Smad-
2 signaling pathway and a nodal- and ALK4-independent signaling pathway 
that leads to the activation of ras/raf/mitogen-activated protein kinase (MAPK) 
and phosphatidylinositol 3-kinase (PI3-K)/AKT signaling pathways implicating 
the glypican-1 receptor. 
Up to know the re-expression of Cripto in adult tissue has been associated 
with cancer. Our unexpected observation that Cripto was also re-expressed 
during muscle regeneration prompted us to perform basic molecular studies, 
both in vitro and in vivo in mouse muscle injury and diseases models, in order 
to better understand the precise nature of the biological effects of Cripto, on 
myogenic cells during post-natal life.  
Our preliminary results shown that Cripto induces in vitro and in vivo cell 
proliferation, myogenic cell migration leading to in vivo faster muscle 
recovery/regeneration after injury. 
Results of the study will be directly beneficial to basic knowledge on cripto 
activity in striated muscle biology and the identification of a molecular system 
operative in cripto-induced regeneration will help to understand mechanisms 
of myofiber regeneration.” 
 
7. Lonardo E., Parish C. , Ponticelli S., Marasco D., De Falco S., Ruvo M. , 
Arenas E. and Minchiotti G. "Identification and characterization of 
molecules involved in neural differentiation of stem cells: improving the 
use of cell-based therapy in neurodegenerative disorders”. XIV 
Convention Telethon, 12-14 marzo 2007. 
“Recent breakthroughs in stem cell research underscore the importance of 
controlling stem cell differentiation for the success of cell-based 
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transplantation therapies in neurodegenerative diseases such as Parkinson 
Disease (PD). In this regard, Embryonic Stem (ES) cells have been shown to 
serve as a source for deriving the optimal dopaminergic (DA) cells to restore 
the nigrostriatal system. However, our knowledge about the molecular 
mechanisms implicated in the determination of the neural fate in ES cells is 
still incomplete and thus their differentiation is poorly controlled. Recent 
findings from our laboratory indicate that the EGF-CFC protein Cripto is a key 
player in the signaling pathways that control neural differentiation of ES cells; 
indeed, disruption of cripto in ES cells results in increased dopaminergic 
differentiation and a reduction in tumor formation upon transplantation in 
Parkinsonian rats (1).  
As an extracellular molecule Cripto is a promising target for therapy (2). We 
have thus exploited a novel experimental approach based on the use of 
combinatorial chemistry combined to ES cell differentiation. By using an 
ELISA-based assay, we have screened a tetrameric tripeptide library 
composed of 27000 molecules and identified two small molecules that 
antagonize Cripto/receptor (Alk4) interaction that have been tested on ES 
cells. Our results show that these blocking peptides, by inhibiting endogenous 
Cripto activity, improve neuronal differentiation of mouse ES cells and 
increase dopaminergic differentiation.  
These molecules will both provide a useful tool for the understanding of the 
mechanisms underlying neural induction in ES cells, and hopefully will have 
important implications for the effective use of stem cells in the treatment of PD, 
by reducing teratoma formation upon transplantation. Worth noting, the ability 
to direct ES cell fate solely hrough the use of extracellular factors, without the 
need to manipulate ES cells genetically, may permit a direct extension of this 
strategy to human cells. 
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Abstract 
 
Embryonic Stem (ES) cells have recently evoked a great 
scientific interest, being valuable both for the study of 
early mammalian development and for regenerative 
medicine. In this respect, several methods have been 
recently described to achieve neuronal differentiation of 
ES cells; however, most of them either require extended 
in vitro culture or give rise to lineage-restricted neuronal 
differentiation. To overcome these limitations, we have 
developed an improved method for preparing mouse ES 
cell aggregates for in vitro neurogenesis studies. This 
protocol relies on the generation of size-controlled 
Embryoid Bodies (EBs) in a chemically-defined serum 
free medium without the addition of any specific factors. 
Neuronal differentiation is assessed by both RT-PCR and 
immunofluorescence analysis. The expression profile of 
multiple neuronal-subtype specific markers is analyzed, 
thus showing that ES-derived EBs undergo a rapid and 
progressive differentiation toward both glial and neuronal 
lineages, giving rise to a wide range of neuronal subtypes 
(i.e. dopaminergic, serotonergic and cholinergic neurons). 
Indeed, a marked temporal correlation in the onset of 
gene expression is observed between ES cell 
differentiation and mouse development. This method 
provides an efficient platform for studying
 
the molecular 
mechanisms underlying the events of multiple neuronal 
subtype specification in ES cells. 
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Introduction 
 
The recent breakthrough in stem cell research 
have opened up new possibilities for cell 
replacement therapy; indeed, cell transplantation 
might help to overcome the intrinsic inability of 
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adult tissues, such as the central nervous system 
(CNS), to replace lost elements. Given their 
expected capacity to self-renew and differentiate 
efficiently into the desired cell type, Embryonic 
Stem (ES) cells represent an invaluable source of 
different cell types. ES cells are derived from the 
inner cell mass of pre-implantation embryos; they 
are amenable to manipulation, enrichment and 
expansion and retain the developmental potency of 
embryonic founder cells, being able to differentiate 
into cells and tissues of all three germ layers both in 
vitro and in vivo [1]. Indeed, differentiation of both 
mouse and human ES cells follows the hierarchical 
set of signals that regulate embryonic development 
in the generation of the germ layers and cell types 
[2-4]; thus, ES cells provide a valid model to 
understand the complex network of signaling 
interactions in the mammalian embryo. 
In this scenario, understanding how specific ES 
cell fate decisions are made is crucial not only to 
fulfill their clinical promise but also to get insights 
into the molecular mechanisms controlling early 
events of mammalian development, eventually 
reactivated in the adult life, in pathological 
conditions. Systematic manipulation of cell cultures 
to direct differentiation of ES cells to specific fates 
requires the development of protocols that 
maximize control over the extrinsic signaling 
environment. In this contest, numerous advances 
were made and several protocols have been 
described that allow differentiation of ES cells into 
neurons [5-10]; however, most of them either 
require extended in vitro culture [7] or result in low 
efficiency of neural induction [8-10]. Worth noting, 
high levels of neural differentiation are induced 
either by treatment of ES-derived EBs with retinoic 
acid (RA) in the presence of serum [5], or by co-
culture with a stromal cell line, PA6 [8]. 
Nevertheless, RA is both a strong teratogen and it is 
supposed to perturb neural patterning, inducing 
suppression of forebrain development [11, 12]; 
moreover, the effect of PA6 cells is attributed to a 
still undefined neural inducing activity known as 
stromal cell-derived inducing activity (SDIA) [6]. 
Recently, efficient neural differentiation of ES 
cell-derived EBs has been reported to occur in 
serum-free conditions; however, it mainly results in 
the generation of telencephalic neurons [13]. 
Finally, very recently, Conti et al. have described a 
method to obtain expandable and homogenous 
neural stem cell population from mouse ES cells 
that generate lineage restricted neurons [14]. 
Here we describe a fast and simple method to 
generate both glial cells and a wide range of 
neuronal subtypes, such as dopaminergic, 
serotonergic and motor neurons from mouse ES 
cells, in the absence of any specific inducing factors 
or extended cultures. 
 
 
Material and Methods 
 
Propagation and Maintenance of ES Cells 
 
Mouse ES cell lines R1 [15] and AK7 [16] have 
been used throughout the study. 
Undifferentiated ES cells were grown on 
mitotically inactivated fibroblast feeder layers and 
maintained in DMEM (Invitrogen, Carlsband, CA, 
http://www.invitrogen.com) supplemented with 
15% fetal bovine serum (Hyclone, Logan, UT, 
http://www.hyclone.com), 0.1 mM "-
mercaptoethanol (Sigma-Aldrich, St. Louis, 
http://www.sigmaaldrich.com), 1 mM sodium 
pyruvate (Invitrogen), 1X non essential aminoacids 
(Invitrogen), 2 mM glutamine (Invitrogen), 
100U/ml penicillin/streptomycin (Invitrogen) and 
10
3
 U/ml leukemia inhibitory factor (LIF) 
(Chemicon International, Temecula, CA, 
http://www.chemicon.com). ES cells were routinely 
passaged every 2 days, and the medium was 
changed on alternated days. 
 
 
Derivation of Neuronal and Glial Cells 
 
High yields of neuronal and glial cells depend 
essentially on two crucial factors: the generation of 
size-controlled Embryoid Bodies (EBs) and the use 
of a chemically-defined medium. 
For neural differentiation, nearly confluent 
100mm-plate of undifferentiated ES cells were 
dissociated in a single-cell suspension by using 
0.25% trypsin (Invitrogen) in PBS, collected by 
centrifugation, resuspended in ES medium and 
plated on 0.1% gelatine coated-100mm dish for 1h 
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at 37°C to remove most of the feeder cells that 
quickly attach to the plate. Cells were collected by 
centrifugation and resuspended at 2 x 10
4
 cells/cm
-2
 
in differentiation medium: Knockout Dulbecco’s 
minimal essential medium supplemented with 15% 
Knockout Serum Replacement (both from 
Invitrogen), 0.1 mM "-mercaptoethanol, 2 mM 
glutamine, 100 U/mL penicillin/streptomycin (from 
now onward KSR medium). EBs differentiation was 
obtained as previously described [17]. Briefly, 20 µl 
drops of ES cells (400 cells/drop) in KSR medium 
were placed on the lid of tissue culture dishes filled 
with PBS and cultivated in hanging drops for 2 days 
(Figure 1). The day on which ES cells were induced 
to aggregate in hanging drops was defined as day 0 
of differentiation. Two-day-old EBs were then 
collected in KSR medium and transferred into 100-
mm bacteriological Petri dishes. After further 3 
days of culture (Figure 1), 5 day-old EBs were 
plated in the same medium either onto 0.1% gelatin-
coated 100-mm tissue culture plates for RT-PCR or 
onto 0.1% gelatin-coated 60-mm dish for IF 
analysis, respectively (Figure 1). At day 10 (5+5) of 
the in vitro differentiation protocol, a population of 
cells with a neuron-like morphology can be clearly 
recognized (Figure 2c). Neuritic outgrowths 
become more complex over the following 3 days 
(Figure 2d). Finally, 13 day-old EBs were processed 
for immunofluorescence and RT-PCR analysis 
(Figure 1), unless stated otherwise. 
 
 
Figure 1. Schematic representation illustrating the sequential steps of KSR-based ES cell differentiation protocol (adapted from 
Maltsev et al., 1993). 
The timeline was counted consecutively from the beginning of differentiation (see text for details). At day 0, undifferentiated ES 
cells were induced to aggregate by hanging drops in KSR medium. After 2 days, EBs were transferred into bacteriological Petri 
dishes for further three days. At day five of differentiation, EBs were induced to adhere and thus plated on either 100mm-gelatine 
coated-dishes for RT-PCR or 60mm gelatine-coated dishes for immunofluorescence analysis. 
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Figure 2. Time-course morphological observation of KSR-derived EBs. 
Phase-contrast images (10x magnification) of RI ES cells differentiated as EBs for 5 (a), 7 (5+2, b), 10 (5+5, c) and 13 (5+8, d) 
days, illustrate the morphological changes and the progressive acquisition of neuronal-like morphology, that generate a complex 
network surrounding the EBs. 
 
RT-PCR 
 
Total RNAs from either undifferentiated ES 
cells or EBs at different stages of differentiation: 5, 
7, 10 and 13 days respectively, were extracted using 
Trizol ultra pure reagent (Invitrogen) according to 
the manufacturer’s instructions and subsequently 
incubated with DNAse RNAse-free (Ambion 
Austin, TX, http://www.ambion.com) to minimize 
genomic DNA contamination. RT Ambion Kit was 
used for reverse transcription. Total RNA (2 µg 
RNA/reaction) was reverse transcribed with 
SuperScript II reverse transcriptase (Invitrogen) 
using random hexamers (New England Biolabs 
Ipswich, MA, http://www.neb.com). cDNA samples 
were subjected to PCR amplification using specific 
primers. Levels of neural markers expression were 
analyzed both in undifferentiated and KSR-
differentiated ES cells. The PCR was carried out 
using standard protocols: Taq polymerase (0.1 
U/reaction, Euroclone, Pero, Italy, 
http://www.euroclone.net), Reaction buffer (1X, 
Euroclone), MgCl2 (1.5 mM, Euroclone), dNTPs 
(0.2 mM, Euroclone). Cycling parameters were as 
follows, denaturation at 94°C for 45 sec, annealing 
at 56°C for 45 sec and elongation at 72°C for 45 
sec. The number of cycles was chosen to select 
PCR conditions on the linear portion of the reaction 
curve avoiding “saturation effects” of PCR. The 
expression of the HPRT housekeeping gene was 
used to normalize PCR reactions. 
Primer sequences, number of cycles and the 
length of the amplified products are provided in 
Table 1. 
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Table 1. Primers used for RT-PCR 
 
Gene Forward primer Reverse primer Size (bp)* Number of cycles 
BF1 actttgagttacaacgggaccacg aaagtaactggtctggcccgc 282 35 
Brachyury gaacctcggattcacatcgtgaga atcaaggaaggctttagcaaatggg 160 35 
ChAT ggccattgtgaagcggtttg tgacatgctcgggctcaggc 425 32 
DAT gtgggcttcactgtcatcctca cccaggtcatcaatgccacga 278 35 
Dlx1 caaggcggggcagctctg gggagacgggcaggaagc 226 35 
EAAT-1 ttggttcgaggacacagtgag caggcccacgattttgtattc 504 32 
En1 tcaagactgactcacagcaacccc tgaatgtccactcggaggatt 564 32 
GAD67 tacggggttcgcacaggtg ccccaagcagcatccacat 600 32 
Gbx2 cggcaacttcgacaaagc agagagaagctctcctcctgc 200 32 
GFAP gctggaggtggagagggaca tggcggcgatagtcgttag 456 32 
HB9 acaggcggctctctatgggaca ttccccaagaggttcgactgc 258 35 
Hoxb4 cctggatgcgcaaagttcac gtgttgggcaacttgtggtc 240 32 
HPRT cctgctggattacattaaagcactg cctgaagtactcattatagtcaagg 369 28 
Isl1 agctgtacgtgctttgttagggatg tcttctcgggctgtttgtgga 390 32 
Lmx1b cctcagcgtgcgtgtggtc agcagtcgctgaggctggtg 323 28 
Math1 cttcctctgggggttactcg aaactctccgtcacttctgtgg 185 35 
MBP aagcacacagcagacccaaagaa aaggatgcccgtgtctctgt 309 32 
Mlc2v gccaagaagcggatagaaggcggg ctgtggttcagggctcagtccttc 490 35 
Nestin cagagaggcgctggaacagagatt agacataggtgggatgggagtgct 460 28 
NF-M gaaatggaagaaaccctcaca ccggccttggcctctggttttgg 474 32 
Nkx2.1 tactgcaacggcaacctg gccatgttcttgctcacgtc 186 35 
Nkx2.2 atgtcgctgaccaacacaaa aaagggctcttaaggggcag 194 32 
Nurr1 ccttgtgttcaggcgcagtatg tggctgtgttgctggtagttgtg 311 32 
Pax7 tgccgatatcaggagactggg ccaggatgccatcgatgc 370 28 
Pitx3 ggaatcgctaccctgacatgag tgaaggcgaacgggaaggtc 270 35 
TH tgtcacgtccccaaggttca gggcaggccgggtctctaagt 276 30 
TpH agacataggtgggatgggagtgct gacatcaaggtcataccgcaac 501 32 
Shh ggaagatcacaagaaactccgaac ggatgtgagctttggattcat 354 32 
* Expected size of PCR products. 
 
Immunocytochemistry 
 
For immunofluorescence analysis, EBs were 
cultured 5 days in suspension and then plated on 
gelatine-coated dishes. EBs were fixed at different 
stages of differentiation in methanol/acetone (7:3) 
on ice for 20 min, or in 4% 
paraformaldehyde/1XPBS at room temperature 
(RT) for 30 min. 
Staining of methanol/acetone fixed EBs: 
following fixation, the EBs were air dried and then 
re-hydrated in 1X PBS for 30 min at room 
temperature. Permeabilization and blocking were 
performed in 5% BSA/0.1% Triton X-100 (Sigma-
Aldrich)/1X PBS for 15 min at RT, followed by 
incubation with 5% BSA in 1X PBS for 30 min at 
RT to minimize background. After blocking, EBs 
were incubated with anti-sarcomeric myosin MF-20 
antibodies (1:50, monoclonal supernatant obtained 
from the Developmental Studies of Hybridoma 
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Bank developed under the auspices of the NICHD 
and maintained by The University of Iowa, 
Department of Biological Sciences, Iowa City, IA 
52242), in 5% BSA /1X PBS for 2 h at RT. 
Following the incubation with primary antibodies, 
EBs were washed 3 times with PBS-0.1% Tween 
for 5 min at RT and further incubated with anti-
mouse Cy3 secondary antibodies (1:400, Molecular 
Probes Inc., Eugene, OR, 
http://probes.invitrogen.com) in 5% BSA /1X PBS 
at RT for 30 min. The EBs were then washed 5 
times with PBS-0.1% Tween for 5 min at RT, 
counterstained with DAPI (250 ng/mL, Sigma-
Aldrich) and mounted with VectaShield medium 
(Vector Laboratories Inc., Burlingame, CA, 
http://www.vectorlabs.com). 
Staining of PFA-fixed EBS: following fixation, 
EBs were washed 3 times with 1X PBS for 5min 
and then incubated with 10% normal goat serum 
(Dako Cytomation, Glostrup, Denmark, 
http://dakocytomation.com)/1% BSA/0.1% Triton 
X-100 in 1X PBS for 15 min at room temperature. 
The EBs were then washed 3 times in 1X PBS for 5 
min and incubated with primary antibodies in 10% 
normal goat serum/1% BSA/1X PBS at the 
following working dilutions: monoclonal anti- "III-
tubulin (1:400; Sigma-Aldrich), monoclonal anti-
nestin (1:10 obtained from the Developmental 
Studies of Hybridoma Bank developed under the 
auspices of the NICHD and maintained by The 
University of Iowa, Department of Biological 
Sciences, Iowa City, IA 52242), polyclonal anti-
GFAP (1:300; Dako Cytomation), polyclonal anti-
TH (1:100; Chemicon International), polyclonal 
anti-GABA (1:100; Chemicon International), 
polyclonal anti-5-HT (1:1000; Sigma-Aldrich); 
monoclonal anti-Islet1 (1:100 obtained from the 
Developmental Studies of Hybridoma Bank 
developed under the auspices of the NICHD and 
maintained by The University of Iowa, Department 
of Biological Sciences, Iowa City, IA 52242), 
monoclonal anti-E-cadherin (1:100, Sigma-
Aldrich). Following primary antibodies incubation, 
EBs were rinsed 3 times in 1X PBS and further 
incubated with secondary antibodies: either goat 
anti-rabbit IgG FITC-conjugated (1:200; Santa Cruz 
Biotechnology, Santa Cruz CA, 
http://www.scbt.com) or goat anti-mouse IgG texas 
red-conjugated (1:400; Molecular Probes) in 1% 
BSA/1X PBS for 30 min at RT. Finally, EBs were 
washed 4 times in 1X PBS, counterstained with 
DAPI (250 ng/mL, Sigma-Aldrich) and mounted in 
VectaShield medium (Vector Laboratories). 
Labeling was visualized by fluorescent illumination 
using an inverted microscope (DMIRB, Leica 
Microsystems, Wetzelar, DE, http://www.leica-
microsystems.com); images were acquired on a DC 
350 FX camera (Leica). 
 
 
 
Results and Discussion 
 
Neural and Glial Differentiation of ES Cells 
with KSR Method 
 
It is well established that ES cell-derived EBs, 
cultured in the presence of high percentage of 
selected serum (15-20% FBS), spontaneously 
differentiate into beating cardiomyocytes [17, 18]. 
In these culture conditions, neuronal differentiation 
is achieved exclusively upon addition of specific 
inducing factors, such as Retinoic Acid [5, 19]. 
Recently, efficient neural conversion of ES cell-
derived EBs has been reported to occur in serum-
free conditions; however, it mainly results in 
lineage restricted neuronal population [13]. Here we 
describe a versatile and fast protocol to generate 
both glial cells and a wide range of neuronal 
subtypes from mouse ES cells, taking advantage of 
a chemically-defined serum free medium (KSR; see 
Materials and Methods) (Figure 1). 
To generate size-controlled EBs, the hanging 
drop-based protocol was used (Figure 1). Following 
EBs formation and suspension culture, 5 day-old 
EBs were plated onto an adhesive substrate and 
differentiation was monitored throughout a period 
of 13 (5+8) days both by morphological analysis, 
gene expression profile and immunofluorescence. 
Starting from day 10 (5+5) of differentiation 
onward, a population of cells showing a neuron-like 
morphology was observed which produce a 
complex network surrounding the aggregates over 
the following 3 days (Figure 2c and d). 
To confirm that those cells were indeed 
neurons, the expression profile of both neural 
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precursor marker (nestin) and neuronal marker (NF-
M) were analyzed, by RT-PCR (Figure 3a). 
 
 
 
Figure 3. Mesodermal and neuroectodermal-derivatives in KSR-derived EBs. 
(a) Expression profile of mesodermal and neuroectodermal specific markers, as analyzed by RT-PCR. RNAs were isolated from 
EBs at different days of differentiation and subjected to RT-PCR using specific primers. The timeline was counted consecutively 
from the beginning of differentiation: undifferentiated ES (0), EBs differentiated for 5, 7 (5+2), 10 (5+5) and 13 (5+8) days. (b-d) 
Immunofluorescence analysis performed on KSR-derived EBs. (b) Nestin/DAPI staining of 7-day-old EBs showed large areas of 
immunoreactive cells (10x magnification). (c) GFAP/"III tubulin double staining of 13-day-old EBs (40x magnification) revealed 
the presence of both astrocytes (green) and neurons (red) in KSR-derived EBs. Cells were counterstained with DAPI (blu). (d) E-
cadherin/DAPI staining of 10-day-old EBs showed areas of E-cadherin-ir
+
 cells (20x magnification) indicating that ectodermal 
tissue was properly formed. 
 
Indeed, expression of both nestin and NF-M 
was already detectable at day 5 of differentiation, 
thus suggesting that a rapid differentiation of ES 
cells into neural lineages occurred in these culture 
conditions. Accordingly, immunofluorescence 
analysis showed that 100% of EBs analyzed were 
immunoreactive to nestin (Figure 3b). Moreover, 
staining with "III-tubulin antibodies revealed the 
presence of large clusters of post-mitotic neurons, 
eventually forming a dense network of neurites in 
13-day-old EBs (Figure 3c). Furthermore, 
spontaneous differentiation of astrocytes occurred 
in KSR-derived EBs, as shown by both RT-PCR 
and immunofluorescence analysis (Figure 3a and c). 
Indeed, GFAP transcripts were detected starting 
from day 10 (5+5) of differentiation; accordingly, 
100% of the 13 day-old EBs that had been 
analyzed, stained positive with anti GFAP 
antibodies (Figure 3a and c). Conversely, MBP-ir
+
 
cells were never detected in our cultures, thus 
suggesting that oligodendrocytes were undetectable 
by immunofluorescence in KSR-derived EBs; 
although, expression of this marker was observed, 
at low levels, by RT-PCR (Figure 3a). 
Our data thus show that KSR-derived EBs 
undergo a rapid and progressive differentiation 
toward the neuronal and glial lineages. In sharp 
contrast, neither "III-tubulin nor GFAP-
immunoreactive cells were ever detected in EBs 
differentiated under standard serum supplemented 
conditions [20] (Figure 4c,e,g,i). 
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Figure 4. Neuronal fate specification of KSR-derived EBs. 
(a) RNAs were isolated from EBs at different days of differentiation and subjected to RT-PCR using specific primers. RT-PCR 
analysis of neural-specific markers showed the presence of multiple neuronal subtypes such as GABA, serotonin, DA, and motor 
neurons starting from days 5-7 of the in vitro differentiation. The timeline was counted consecutively from the beginning of 
differentiation: undifferentiated ES (0), EBs differentiated for 5, 7 (5+2), 10 (5+5) and 13 (5+8) days. RNAs from adult mouse 
brain were used as positive control. According to RT-PCR results (a) double staining of "III tubulin with TH (b), serotonin (5-HT, 
d), GABA (f) antibodies (63x magnification) and Islet antibodies (g) (40x magnification), showed a marked presence of mid-
hindbrain and spinal cord neurons in EBs differentiated by KSR protocol. In sharp contrast, we never observed positive staining 
using the same antibodies in EBs differentiated under standard serum supplemented conditions (c, e, g, i). 
 
Having shown that KSR-derived EBs 
efficiently differentiate into neuroectodermal-
derived cells, we asked whether induction of 
neuronal markers was accompanied by the presence 
of non-neural ectodermal tissue. To this end, 
immunofluorescence analysis was performed using 
anti E-cadherin antibodies, staining the non-neural 
ectodermal cells. Indeed, 100% of EBs analyzed 
showed areas of E-cadherin-immunoreactive cells 
(Figure. 3d), thus indicating proper formation of the 
ectodermal lineage in these culture conditions. 
We thus went on to evaluate whether efficient 
neural differentiation resulted in impaired 
differentiation of mesodermal tissues in KSR-
derived EBs. To this end, the expression profile of 
both the pan-mesodermal marker Brachyury and the 
cardiac-specific marker Mlc2v, was analyzed by 
RT-PCR (Figure. 3a). Both genes are expressed in a 
time-dependent manner during EBs differentiation 
in serum-containing medium ([20, 21] and data not 
shown); in sharp contrast, expression of Brachyury 
and Mlc2v was hardly detected in KSR-derived 
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EBs, thus suggesting that mesodermal induction and 
differentiation was impaired in these culture 
conditions. Accordingly, a small percentage (10%) 
of KSR-derived EBs showed few MF-20-ir
+
 cells 
(data not shown). Taken together, our results 
indicate that the KSR-protocol favors differentiation 
into neuro-ectodermal lineages. 
 
 
Generation of Multiple Neuronal Subtypes in 
KSR-Derived EBs 
 
Previous reports have shown that multiple 
neuronal subtypes can be derived from mouse ES 
cells either by co-culture with stromal cells [6, 9] or 
by induction with specific inducing factors [5, 19]. 
Furthermore, very recently, the generation of ES-
derived neurons has been reported to occur in serum 
free cultures [13], or in adherent culture in presence 
of specific growth factors [14]. Worth noting, both 
protocols result in highly efficient neuronal 
induction and differentiation of ES cells; 
nevertheless, lineage restricted sub-neuronal 
population was obtained. 
Having shown that KSR-derived EBs 
underwent rapid and efficient neuronal 
differentiation, we went on to assess whether 
different neuronal subtypes could be derived in 
these culture conditions. To this end, the time-
dependent expression profile of specific neuronal 
markers was analyzed by RT-PCR and, 
furthermore, immunofluorescence analysis was 
performed using anti-"III-tubulin antibodies in 
combination with markers of different neuronal 
subtypes. We first evaluated the presence of 
neurons expressing the tyrosine hydroxylase (TH), 
the rate-limiting enzyme in dopamine biosynthesis. 
Interestingly, almost 100% of 13 day-old EBs 
analyzed showed clusters of TH-immunoreactive 
neurons (Figure 4b). Consistent with these results, 
the dopamine transporter (DAT) was highly 
expressed (Figure 4a); thus revealing the presence 
of dopaminergic neurons in KSR-derived EBs. 
Furthermore, the presence of serotonin (5-HT) 
immunoreactive cells within the cultures indicated 
that serotonergic neurons were also present in 100% 
of EBs analyzed (Figure 4d). Accordingly, the 
serotonin biosynthetic enzyme tryptophan 
hydroxylase (TpH) was highly expressed (Figure 
4a). Worth noting, GABA-ir
+
 cells were observed 
only in 25% of the EBs analyzed (Figure. 4f), thus 
revealing the presence of rare GABAergic neurons, 
that is consistent with the expression of the 
glutamate decarboxilase GAD67 gene, detected by 
RT-PCR (Figure 4a). Furthermore, the excitatory 
aminoacid transporter EAAT transcript was also 
detected (Figure 4a); thus suggesting that 
glutamatergic neurons were also present in these 
cultures. Finally, 50% of the EBs analyzed showed 
areas of Isl1-ir
+
 cells thus indicating the presence of 
cholinergic neurons (Figure 4h). The generation of 
these neuronal sub-types was consistent with the 
presence in these cultures of both mid-hindbrain 
(En1, Nurr 1, Lmx1b, Pitx3 and Nkx2.2), spinal 
cord (HB9, ChAT) and forebrain (Dlx1) specific 
transcripts (Figures 4a, 5). 
Worth noting, we never detected 
immunoreactive cells using TH (Figure 4c), 
serotonin (Figure 4e), GABA (Figure. 4g), and Isl1 
(Figure 4i) antibodies in EBs differentiated under 
standard serum supplemented conditions. 
It is well known that early exposure to Shh 
during ES cell differentiation induces the 
expression of ventral markers and is required for 
enriching in dopaminergic, serotonergic and 
cholinergic neurons [22, 23]. Based on these 
considerations and on our results, we evaluated the 
expression of Shh in KSR-derived EBs cultures, by 
RT-PCR. Indeed, expression of Shh was highly 
induced already in 5 day-old KSR-derived EBs, 
persisting at high levels up to day 13 (Figure 4a); 
thus leading to hypothesize that early endogenous 
expression of Shh might reflect the high default 
prevalence of ventral neuronal subtypes observed in 
these cultures. 
 
 
Brain regional markers expressed by ES cell-
derived neurons in KSR culture condition 
 
With the aim to better characterize the nature of 
the ES cell-derived neurons in KSR culture 
conditions, we analyzed the expression of rostral-
caudal CNS markers, by RT-PCR. Interestingly, 
KSR-differentiated EBs express the spinal cord 
marker Hoxb4, the hindbrain marker Gbx2, the 
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midbrain marker En1 as well as the forebrain 
marker Dlx1, whereas expression of telencephalic 
markers BF1 and Nkx2.1 were barely detected 
(Figure 5). These results indicate that KSR-
differentiated ES cells give raise to a variety of 
neuronal cell types along rostro-caudal axis, with 
the exception of the rostral most cells of the CNS. 
Interestingly, Watanabe and colleagues have 
recently shown that a marked increase in 
telencephalic neurons can be obtained upon 
neuronal differentiation of ES cell in similar serum-
free culture conditions; however, EBs were 
generated by spontaneous aggregation in suspension 
culture and additional inducing factors were used 
that might explain the different neuronal subtypes 
generated. Indeed, ES cells were cultured in the 
presence of GMEM supplemented with N2 and, in 
addition, the EBs were plated on poly-D-lysine, 
laminin and fibronectin coated dishes from day 5 of 
differentiation [13]. 
 
 
Figure 5. Positional identity of KSR-derived neurons. 
RNAs were isolated from EBs at different days of 
differentiation and subjected to RT-PCR using specific 
primers. The timeline was counted consecutively from the 
beginning of differentiation: undifferentiated ES (0), EBs 
differentiated for 5, 7 (5+2), 10 (5+5) and 13 (5+8) days. 
Expression profile of rostro-caudal (BF1, Nkx2.1, Dlx1, 
En1, Gbx2, Hoxb4) and dorso-ventral (Math1, Pax7, Gbx2, 
Nkx2.2, Dlx1, Nkx2.1) markers revealed the presence of a 
variety of dorso-ventral as well as rostro-caudal neurons 
within the cultures. 
Finally, to further characterize the neuronal 
subtypes generated by the KSR protocol, we 
examined the expression profile of positional 
markers along the dorsal-ventral axis in KSR 
culture conditions (Figure. 5). The ventral markers 
Nkx2.2, Dlx1 and Gbx2 were all expressed in KSR-
derived EBs. Moreover, the dorsal marker Pax7 was 
expressed in KSR culture conditions starting from 
day seven, whereas, in sharp contrast, expression of 
Math1 marker, which identifies the dorsal-most 
interneuron progenitors, was not detected. These 
results suggest that KSR-derived EBs have the 
competence to differentiate into a variety of dorsal 
and ventral cells of the CNS except for the dorsal 
most cells of the neural tube. 
 
 
Conclusions 
 
In this study, we describe a rapid and versatile 
method to generate a wide range of neural subtypes 
from mouse ES cells. Indeed, we have shown that 
neurons expressing positional markers characteristic 
of midbrain, hindbrain and spinal cord can be easily 
and rapidly generated. Moreover, ES cells remain 
amenable to dorso-ventral neural patterning and 
may thus serve as a universal source for neuronal 
subtype-specific differentiation. Finally, in KSR-
based ES cell differentiation protocol the temporal 
expression profile of genes involved in early 
neuronal commitment and differentiation (i.e. 
nestin, TH, ChAT, Nurr1, GAD67, Pitx3), 
gliogenesis (GFAP) as well as of genes involved in 
anterior-posterior and dorso-ventral patterning (i.e. 
Dlx1, Hoxb4, Pax7 and Nkx2.2) generally 
mimicked that observed in mouse embryo [9]. In 
this respect, the reported protocol would be very 
useful to improve our knowledge of the molecular 
mechanisms underlying neuronal differentiation in 
mammalian cells. Furthermore, we believe that, 
upon addition of defined cocktail of growth factors 
and/or extra-cellular matrix components, this 
protocol might be useful to obtain lineage restricted 
neuronal population, thus representing a valuable 
source of neuronal subtypes for transplantation 
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experiments in animal models of neurodegenerative 
diseases. 
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